

***Core indicators for monitoring the Ending the HIV Epidemic initiative,
data reported through December 2019***

Advisory Statement

Effective date: May 21, 2024

Publication date of referenced document: March 2020

Preexposure prophylaxis (PrEP) coverage is currently estimated by taking the number of persons prescribed PrEP (numerator) and dividing it by the estimated number of persons with indications for PrEP (denominator). Since the current methodology for estimating PrEP coverage was first published in 2018, CDC has cited limitations of both the numerator and denominator. For example, the number of persons prescribed PrEP is estimated by using data from the IQVIA pharmacy database based on an algorithm that includes FDA-approved drugs for PrEP. Although IQVIA records 94% of all prescriptions from retail pharmacies and 74% from mail-order outlets in the United States, data from closed health care systems are not included in the IQVIA data set. Therefore, the current PrEP numerator has represented minimum estimates of PrEP prescriptions. Additionally, race/ethnicity data in the IQVIA database are only available for <40% of persons prescribed PrEP each year. Regarding limitations of the current denominator, the number of persons who have indications for PrEP is estimated by using data from 3 sources: National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Each of these data sources have different schedules of data availability. As a result, the availability of a denominator often lags the availability of a numerator.

In March 2024, updated data from 2 closed-system sources were made available to CDC that can improve the representativeness of the number of persons prescribed PrEP in the United States. In the coming months, CDC also expects to have updates to the data sets currently used to estimate the number of persons with indications for PrEP. To ensure that PrEP coverage estimates are calculated using the best available data at the time of publication, CDC is pausing PrEP coverage reporting for one year. During this time, CDC will update PrEP coverage data sources and determine the best way to present PrEP coverage. CDC plans to resume PrEP coverage reporting in the next HIV Surveillance Supplemental (Monitoring) Report, currently scheduled for publication in June 2025.

Until updated estimates are published, CDC advises against citing specific PrEP coverage data points and instead recommends referencing general trends and disparities. In addition, because of a formula error that affects a subset of race and ethnicity PrEP data, race and ethnicity data points from all reports published prior to 2024 should not be cited.



Early Release

Core Indicators for Monitoring the Ending the HIV Epidemic Initiative

(Data reported through December 2019)

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV/AIDS Prevention (DHAP), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through December 2019.

HIV Surveillance Data Tables is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

Suggested citation

Centers for Disease Control and Prevention. HIV Surveillance Data Tables (early release): Core indicators for monitoring the Ending the HIV Epidemic initiative, data reported through December 2019. <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Published March 2020. Accessed [date].

On the Web: <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>

Confidential information, referrals, and educational material on HIV infection and AIDS

CDC-INFO

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

<http://wwwn.cdc.gov/dcs/ContactUs/Form>

Acknowledgments

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

HIV Surveillance Data Tables was prepared by the following staff and contractors of the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC: Anna Satcher Johnson, Zanetta Gant, Ya-lin Huang, Dawn Smith, Rick Song, André Dailey, William Adih, Shacara Johnson, Baohua Wu, Chan Jin, Xiaohong Hu, Chenchen Yu, Irene Hall, Norma Harris, and Michael Friend (editing and desktop publishing).

Technical Notes	5
References	7
Tables	
1a Estimated HIV incidence among persons aged ≥ 13 years, by selected characteristics, 2017 and 2018—United States	8
1b Estimated HIV incidence among persons aged ≥ 13 years, by area of residence, 2017 and 2018—United States and Puerto Rico	9
1c Estimated HIV incidence among persons aged ≥ 13 years, by area of residence, 2017 and 2018—Ending the HIV Epidemic Phase I jurisdictions	10
2a Estimated HIV prevalence among persons aged ≥ 13 years, by selected characteristics, 2017 and 2018—United States	12
2b Estimated HIV prevalence among persons aged ≥ 13 years, by area of residence, 2017 and 2018—United States and Puerto Rico	14
2c Estimated HIV prevalence among persons aged ≥ 13 years, by area of residence, 2017 and 2018—Ending the HIV Epidemic Phase I jurisdictions	16
3a Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, 2017 and 2018—United States	20
3b Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, 2017 and 2018—United States and 6 dependent areas	21
3c Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, 2017 and 2018—United States and 6 dependent areas	22
3d Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, 2017 and 2018—Ending the HIV Epidemic Phase I jurisdictions	23
4a Linkage to HIV medical care within 1 month after HIV diagnosis during 2017, among persons aged ≥ 13 years, by selected characteristics—41 states and the District of Columbia	25
4b Linkage to HIV medical care within 1 month after HIV diagnosis during 2017, among persons aged ≥ 13 years, by area of residence—41 states and the District of Columbia	26
4c Linkage to HIV medical care within 1 month after HIV diagnosis during 2017, among persons aged ≥ 13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions	27
4d Linkage to HIV medical care within 1 month after HIV diagnosis during 2018, among persons aged ≥ 13 years, by selected characteristics—41 states and the District of Columbia	29
4e Linkage to HIV medical care within 1 month after HIV diagnosis during 2018, among persons aged ≥ 13 years, by area of residence—41 states and the District of Columbia	30
4f Linkage to HIV medical care within 1 month after HIV diagnosis during 2018, among persons aged ≥ 13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions	31
5a HIV viral suppression during 2017 among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2016 and alive at year-end 2017, by selected characteristics—41 states and the District of Columbia	33
5b HIV viral suppression during 2017 among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2016 and alive at year-end 2017, by area of residence—41 states and the District of Columbia	34
5c HIV viral suppression during 2017 among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2016 and alive at year-end 2017, by area of residence—Ending the HIV Epidemic Phase I jurisdictions	35
5d HIV viral suppression during 2018 among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2017 and alive at year-end 2018, by selected characteristics—41 states and the District of Columbia	37

5e	HIV viral suppression during 2018 among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2017 and alive at year-end 2018, by area of residence—41 states and the District of Columbia	38
5f	HIV viral suppression during 2018 among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2017 and alive at year-end 2018, by area of residence—Ending the HIV Epidemic Phase I jurisdictions	39
6a	Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2017, among persons aged ≥ 16 years, by selected characteristics—United States	41
6b	Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2017, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico	42
6c	Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2017, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions	43
6d	Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2018, among persons aged ≥ 16 years, by selected characteristics—United States	45
6e	Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2018, among persons aged ≥ 16 years, by area of residence—United States	46
6f	Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2018, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions	47
7	Ending the HIV Epidemic Phase I jurisdictions	49

The *Ending the HIV Epidemic: A Plan for America* (EHE) initiative will leverage critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% in 5 years, and by at least 90% in 10 years.

The included early release tables provide data on the core indicators that will be used to monitor the EHE initiative. Data are provisional and will be updated in future releases. National-, state-, and county-level (EHE Phase I jurisdictions only; see Table 7) data are provided for the 6 core indicators of the EHE initiative, which are the following:

- **New HIV infections:** the estimated number of new HIV infections in a calendar year.
- **Knowledge of HIV status:** the percentage of persons with HIV who have received a diagnosis.
- **HIV diagnoses:** the number of HIV infections confirmed by laboratory or clinical evidence in a calendar year.
- **Linkage to HIV medical care:** the percentage of persons who have received a diagnosis of HIV infection in a calendar year and were linked to HIV medical care within 1 month.
- **HIV viral suppression:** the percentage of persons living with diagnosed HIV who have a suppressed viral load at the most recent test in a calendar year.
- **Preexposure prophylaxis (PrEP) coverage:** the percentage of the estimated number of persons prescribed PrEP in a calendar year relative to the estimated number of persons with indications for PrEP in a calendar year.

SURVEILLANCE OF HIV INFECTION

Data presented were reported (after the removal of personally identifiable information) to the Centers for Disease Control and Prevention (CDC) through December 31, 2019. Please use caution when interpreting the following:

- Data on diagnoses of HIV infection. HIV surveillance reports may not be representative of all persons with HIV because not all infected persons have been (1) tested or (2) tested at a time when the infection could be detected and diagnosed. Also, some states offer anonymous HIV testing;

the results of anonymous tests are not reported to the confidential, name-based HIV registries of state and local health departments. Therefore, reports of confidential test results may not represent all persons who tested positive for HIV infection.

- Deaths and prevalence-based data (knowledge of status and HIV viral suppression). Data for the year 2018 are preliminary and based on deaths reported to CDC as of December 2019.
- Numbers less than 12 and trends based on these numbers.

TABULATION AND PRESENTATION OF DATA

New HIV Infections

New HIV infections among persons aged ≥ 13 years are estimated using the first CD4+ T-lymphocyte (CD4) test result after HIV diagnosis and a CD4-depletion model indicating disease progression or duration after infection (Tables 1a–c).

More information on estimating new HIV infections can be found at <https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-24-1.pdf> (*Estimated HIV incidence and prevalence in the United States, 2010–2016*).

HIV Prevalence and Diagnosed Infection

The Knowledge of HIV Status indicator is measured as the percentage of persons aged ≥ 13 years with diagnosed HIV infection (Tables 2a–c). For this measure the numerator (data reported to CDC) is the number of persons aged ≥ 13 years living with diagnosed HIV infection at the end of the year. The denominator, total HIV prevalence, is the estimated number of persons aged years living with HIV infection (diagnosed or undiagnosed) at the end of the year. Knowledge of status and prevalence data for the year 2018 are preliminary and based on death data reported to CDC as of December 2019. The following areas had incomplete reporting of deaths for the year 2018, and prevalence estimates should be interpreted with caution: Alabama, Oklahoma, and South Carolina. Estimates for areas without laws requiring reporting of laboratory data, or with incomplete reporting of laboratory data to CDC, should also be interpreted with caution.

Areas without laws: Idaho, New Jersey, Pennsylvania.
Areas with incomplete reporting: Arizona, Arkansas, Connecticut (2018 only), Kansas, Kentucky, Nevada (2017 only), Vermont, and Puerto Rico.

More information on calculating HIV prevalence and percentage of persons with diagnosed HIV infection can be found at <https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-24-1.pdf> (*Estimated HIV incidence and prevalence in the United States, 2010–2016*).

Diagnoses of HIV Infection

Diagnoses of HIV infection are the numbers of persons aged ≥ 13 years with HIV diagnosed during the specified years (Tables 3a–d).

More information on counting diagnoses of HIV infection can be found at <https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2018-vol-30.pdf> (*HIV Surveillance Report, 2018*).

Linkage to HIV Medical Care

Linkage to HIV medical care within one month of HIV diagnosis is measured for persons aged ≥ 13 years whose infection was diagnosed during the specified year, and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 4a–f). The numerator is the number of persons aged ≥ 13 years with HIV diagnosed during the specified year and who had ≥ 1 CD4 or viral load (VL) test within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥ 13 years with HIV infection diagnosed during the specified year. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete reporting: Arizona, Arkansas, Connecticut (2018 only), Kansas, Kentucky, Nevada (2017 only), Vermont, and Puerto Rico.

More information on calculating linkage to care can be found at <https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-24-3.pdf> (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2017*).

Viral Suppression

Viral suppression at most recent test during the specified year is measured for persons aged ≥ 13 years who resided, as of their most recent known address during the specified year, in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC, and who were alive at the end of the specified year (Tables 5a–f). The numerator is the number of persons aged ≥ 13 years with HIV infection diagnosed by the end of the prior year, and who had a VL < 200 copies/mL at the most recent test in the specified year. The denominator is the number of persons aged ≥ 13 years with HIV diagnosed by the end of the prior year, and who were alive at the end of the specified year. Viral suppression data for the year 2018 are preliminary. Data used to calculate prevalence are based on deaths reported to CDC as of December 2019. The following areas had incomplete reporting of deaths for the year 2018, and viral suppression data should be interpreted with caution: Alabama, Oklahoma, and South Carolina. Data are not provided for states and associated EHE Phase I jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Connecticut (2018 only), Kansas, Kentucky, Nevada (2017 only), Vermont, and Puerto Rico.

More information on calculating viral suppression can be found at <https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-24-3.pdf> (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2017*).

Preexposure Prophylaxis (PrEP) Coverage

PrEP coverage, reported as a percentage, is defined as the number of persons aged ≥ 16 years who have been prescribed PrEP during the specified year divided by the estimated number of persons aged ≥ 16 years who had indications for PrEP during the specified year (Tables 6a–f).

Please use caution when interpreting PrEP data. Different data sources were used in the numerator and denominator to calculate PrEP coverage.

Persons prescribed PrEP

National pharmacy data from the IQVIA Real World Data—Longitudinal Prescriptions database (hereafter, IQVIA database) are used to classify persons aged ≥ 16 years who have been prescribed PrEP in the specific year. The IQVIA database captures prescriptions from all payers and represents approximately 92% of all prescriptions from retail pharmacies and 60%–86% from mail-order outlets in the United States. The database does not include prescriptions from some closed health care systems that do not make their prescription data available to IQVIA. Therefore, these are minimum estimates of PrEP coverage. The annual number of persons classified as having been prescribed PrEP was based on a validated algorithm that discerns whether tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) were prescribed for PrEP after excluding prescriptions for HIV treatment, hepatitis B treatment, or HIV postexposure prophylaxis [2, 3].

The number of persons classified as having been prescribed PrEP is reported by sex, age group, and race/ethnicity. Transmission category data are not available in the IQVIA database and race/ethnicity data are available for $<40\%$ of persons with PrEP prescriptions. Please use caution when interpreting PrEP data by race/ethnicity. Race/ethnicity categories available in the IQVIA data include white, black, Hispanic, and other. The number of persons prescribed PrEP for each racial/ethnic group presented in this report are extrapolated by applying the racial/ethnic distribution of known records to those for which data on race/ethnicity were unknown.

Geographic Designations

In the IQVIA database, a person's location is reported as a 3-digit ZIP code prefix (hereafter, ZIP3) assigned by the U.S. Postal Service. To estimate the number of persons prescribed PrEP at the state or county level, a probability-based approach is used to crosswalk between ZIP3s and states/counties by using data from (a) the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates by ZIP code Tabulate Area (ZCTA) [4], and (b) the U.S. Department of Housing and Urban Development's ZIP Code Crosswalk Files [5]. Because of reliability concerns, subnational estimates of <40 are not included in this report.

Persons with PrEP indications

ACS and U.S. Census Bureau datasets were used to estimate the number of men who have sex with men

(MSM) in a jurisdiction. Next, behavioral data from the National Health and Nutrition Examination Survey (NHANES) were used to estimate the proportion of HIV-negative MSM with indications for PrEP [6].

Finally, the number of HIV-negative MSM with indications for PrEP was multiplied by the ratio of percentage of diagnoses during the specified year attributed to other major transmission risk groups compared to the percentage among MSM in a given state or county. The estimated number of persons with indications for PrEP in the 3 major transmission risk groups (MSM, heterosexuals, persons who inject drugs) in each jurisdiction were then summed to yield a state- or county-specific estimate. State estimates were then summed for a national total of persons with indications for PrEP [7].

REFERENCES

1. HHS. What is 'Ending the HIV Epidemic: A Plan for America'? <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>. Published October 4, 2019. Accessed March 5, 2020.
2. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons—United States, 2010–2014. *Clin Infect Dis* 2017; 64(2):144–149. doi:10.1093/cid/ciw701.
3. CDC [Huang YA, Zhu W, Smith DK, Harris N, Hoover KW]. HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016. *MMWR* 2018;67(41):1147–1150. doi:10.15585/mmwr.mm6741a3.
4. U.S. Census Bureau. American Community Survey 5-year data (2009–2018). <https://www.census.gov/data/developers/data-sets/acs-5year.2016.html>. Published December 19, 2019. Accessed March 4, 2020.
5. HUD. HUD USPS ZIP code crosswalk files. https://www.huduser.gov/portal/datasets/usps_crosswalk.html. Published 2019. Accessed March 4, 2020.
6. CDC [Smith DK, Van Handel M, Wolitski RJ, et al]. Vital Signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. *MMWR* 2015;64(46):1291–1295. doi:10.15585/mmwr.mm6446a4.
7. Smith DK, Van Handel M, Grey J. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. *Ann Epidemiol* 2018;28(12):850–857.e9. doi:10.1016/j.annepidem.2018.05.003.

Table 1a. Estimated HIV incidence among persons aged ≥ 13 years, by selected characteristics, 2017 and 2018—United States

	2017			2018		
	No.	RSE (%)	95% CI	No.	RSE (%)	95% CI
Sex at birth						
Male	30,300	3.1	28,400–32,100	29,700	3.7	27,500–31,900
Female	6,700	5.7	6,000–7,500	6,700	6.5	5,900–7,600
Age at infection (yr)						
13–24	8,200	5.9	7,300–9,200	7,600	7.2	6,500–8,700
25–34	14,400	4.4	13,200–15,700	14,400	5.2	12,900–15,900
35–44	6,900	6.3	6,100–7,800	7,000	7.4	6,000–8,000
45–54	4,400	7.8	3,800–5,100	4,200	9.4	3,500–5,000
≥55	3,000	9.5	2,400–3,600	3,200	10.7	2,500–3,800
Race/ethnicity						
American Indian/Alaska Native	*190	*38.3	*50–*340	*210	*43.9	*30–*380
Asian	610	22.3	340–870	620	26.4	300–940
Black/African American	15,500	4.2	14,200–16,800	15,300	4.9	13,800–16,800
Hispanic/Latino ^a	10,200	5.7	9,000–11,300	10,300	6.7	9,000–11,700
Native Hawaiian/other Pacific Islander
White	9,400	5.0	8,500–10,300	9,000	5.9	7,900–10,000
Multiple races	1,100	16.3	760–1,500	910	21.2	530–1,300
Transmission category^b						
Male-to-male sexual contact	25,300	3.4	23,600–27,000	24,400	4.1	22,400–26,400
Injection drug use	2,200	10.0	1,800–2,700	2,400	11.4	1,900–2,900
Male	1,300	14.1	910–1,600	1,400	15.6	970–1,800
Female	1,000	14.0	720–1,300	1,000	16.3	680–1,300
Male-to-male sexual contact and injection drug use	1,200	12.9	920–1,500	1,400	13.8	1,000–1,700
Heterosexual contact ^c	8,200	5.8	7,300–9,200	8,200	6.6	7,100–9,300
Male	2,500	12.7	1,900–3,100	2,500	14.4	1,800–3,200
Female	5,700	6.3	5,000–6,400	5,700	7.1	4,900–6,500
Region of residence						
Northeast	5,100	7.4	4,400–5,900	5,000	8.8	4,100–5,900
Midwest	5,000	7.3	4,200–5,700	4,700	8.9	3,800–5,500
South	19,300	3.8	17,800–20,700	19,200	4.5	17,500–20,900
West	7,700	6.1	6,800–8,600	7,500	7.3	6,500–8,600
Total^d	37,000	2.7	35,000–39,000	36,400	3.3	34,100–38,700

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Estimates derived by using HIV surveillance and CD4 data for persons aged ≥13 years at diagnosis.

Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty.

Estimates with an RSE of 30%–50% are preceded by an asterisk (*) and should be used with caution because they do not meet the standard of reliability.

Estimates with an RSE of >50% are not shown and are replaced by an ellipsis (...).

^a Hispanics/Latinos can be of any race.

^b Data by transmission category have been statistically adjusted to account for missing risk-factor information.

^c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^d Includes persons with HIV infection attributed to hemophilia or blood transfusion, or whose risk factor was not reported or identified.

**Table 1b. Estimated HIV incidence among persons aged ≥ 13 years, by area of residence, 2017 and 2018—
United States and Puerto Rico**

Area of residence	2017			2018		
	No.	RSE (%)	95% CI	No.	RSE (%)	95% CI
Alabama	630	20.3	380–880	580	24.5	300–870
Alaska
Arizona ^a	800	19.6	490–1,100	850	22.4	480–1,200
Arkansas ^a	*300	*32.8	*110–*500	*250	*43.5	*40–*460
California	4,800	7.4	4,100–5,500	4,600	8.9	3,800–5,300
Colorado	470	23.7	250–690	*380	*32.8	*140–*620
Connecticut ^a	*240	*32.0	*90–*390	*190	*43.2	*30–*350
Delaware	140	*43.5	20–260
District of Columbia	*210	*31.8	*80–*340	*210	*34.8	*70–*350
Florida	4,400	7.3	3,700–5,000	4,300	8.5	3,600–5,000
Georgia	2,500	10.5	2,000–3,100	2,600	12.4	1,900–3,200
Hawaii	*110	*47.8	*10–*220
Idaho ^a
Illinois	1,400	14.0	990–1,700	1,300	16.9	880–1,700
Indiana	550	24.9	280–820	590	28.1	260–910
Iowa
Kansas ^a
Kentucky ^a	350	29.4	150–550	440	29.9	180–690
Louisiana	1,100	16.7	730–1,400	1,100	18.9	720–1,600
Maine
Maryland	750	18.2	480–1,000	850	18.4	540–1,200
Massachusetts	580	20.3	350–820	710	20.5	430–1,000
Michigan	730	20.2	440–1,000	700	24.3	360–1,000
Minnesota	*230	*34.4	*70–*380	*310	*34.0	*100–*520
Mississippi	*470	*30.8	*180–*750	*430	*38.8	*100–*750
Missouri	540	20.1	330–760	450	27.0	210–690
Montana
Nebraska	*120	*47.8	*10–*230
Nevada ^a	600	24.0	320–880	650	27.1	310–1,000
New Hampshire
New Jersey ^a	1,100	17.7	710–1,500	950	22.4	530–1,400
New Mexico	*130	*44.4	*20–*240
New York	2,200	10.7	1,800–2,700	2,100	12.9	1,600–2,600
North Carolina	1,100	13.9	830–1,500	970	18.2	620–1,300
North Dakota
Ohio	950	17.0	640–1,300	880	20.8	520–1,200
Oklahoma	320	28.5	140–510	*310	*37.7	*80–*540
Oregon	*200	*37.6	*50–*360	*210	*45.3	*20–*400
Pennsylvania ^a	940	24.5	490–1,400	890	26.7	430–1,400
Puerto Rico ^a	400	25.4	200–600	*330	*31.5	*130–*540
Rhode Island
South Carolina	700	22.7	390–1,000	700	27.0	330–1,100
South Dakota
Tennessee	670	17.9	440–910	660	20.6	390–920
Texas	4,400	8.0	3,700–5,100	4,600	9.2	3,800–5,400
Utah	*120	*45.6	*10–*220
Vermont ^a
Virginia	850	17.8	550–1,100	800	21.4	460–1,100
Washington	480	24.5	250–720	540	27.1	250–830
West Virginia
Wisconsin	*240	*33.4	*80–*390	*190	*45.4	*20–*360
Wyoming

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Estimates derived by using HIV surveillance and CD4 data for persons aged ≥ 13 years at diagnosis. Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty. Estimates with an RSE of 30%–50% are preceded by an asterisk (*) and should be used with caution because they do not meet the standard of reliability. Estimates with an RSE of >50% are not shown and are replaced by an ellipsis (...).

^a Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete reporting: Arizona, Arkansas, Connecticut (2018 only), Kansas, Kentucky, Nevada (2017 only), Vermont, and Puerto Rico.

**Table 1c. Estimated HIV incidence among persons aged ≥ 13 years, by area of residence, 2017 and 2018—
Ending the HIV Epidemic Phase I jurisdictions**

Area of residence	2017			2018		
	No.	RSE (%)	95% CI	No.	RSE (%)	95% CI
Arizona						
Maricopa County ^a	530	22.8	290–760	560	25.9	280–850
California						
Alameda County	*190	*36.1	*60–*320	*180	*43.5	*30–*330
Los Angeles County	1,500	12.8	1,100–1,900	1,400	15.7	950–1,800
Orange County	290	29.0	130–460	*270	*35.3	*80–*460
Riverside County	*280	*30.1	*110–*440	*280	*34.7	*90–*470
Sacramento County	*230	*32.6	*80–*380	*180	*44.0	*20–*330
San Bernardino County	*260	*31.0	*100–*420	*260	*36.1	*80–*450
San Diego County	480	22.8	260–690	440	27.6	200–690
San Francisco County	*180	*37.5	*50–*310	*170	*44.6	*20–*320
District of Columbia	*210	*31.8	*80–*340	*210	*34.8	*70–*350
Florida						
Broward County	670	17.7	440–900	580	21.9	330–830
Duval County	250	28.7	110–400	*210	*36.3	*60–*360
Hillsborough County	280	27.1	130–440	*280	*31.4	*110–*460
Miami-Dade County	1,100	13.6	830–1,400	1,100	15.6	790–1,500
Orange County	420	22.4	230–600	450	25.0	230–670
Palm Beach County	270	27.7	120–420	*240	*33.8	*80–*410
Pinellas County	*140	*38.7	*30–*250	*140	*44.1	*20–*270
Georgia						
Cobb County	*180	*37.4	*50–*310
DeKalb County	350	26.8	160–530	*400	*30.0	*160–*640
Fulton County	560	21.1	330–790	670	23.2	370–980
Gwinnett County	*150	*41.4	*30–*260	*150	*49.8	*0–*290
Illinois						
Cook County	1,000	16.0	690–1,300	910	20.0	550–1,300
Indiana						
Marion County	*250	*34.9	*80–*420	*230	*42.7	*40–*430
Louisiana						
East Baton Rouge Parish	*190	*35.0	*60–*330	*210	*38.7	*50–*380
Orleans Parish	*190	*35.8	*60–*320	*180	*42.5	*30–*330
Maryland						
Baltimore City	*180	*37.1	*50–*310	*210	*36.7	*60–*370
Montgomery County	*110	*47.4	*10–*220
Prince George's County	*200	*35.9	*60–*330	*270	*32.9	*90–*440
Massachusetts						
Suffolk County	*140	*41.4	*30–*260	*140	*45.5	*10–*260
Michigan						
Wayne County	310	28.8	130–490	*300	*35.2	*90–*510
Nevada						
Clark County ^a	540	24.5	280–800	590	27.8	270–920
New Jersey						
Essex County ^a	*330	*30.0	*140–*520	*220	*43.8	*30–*410
Hudson County ^a	*160	*43.4	*20–*300	*190	*48.0	*10–*360

Table 1c. Estimated HIV incidence among persons aged ≥ 13 years, by area of residence, 2017 and 2018—Ending the HIV Epidemic Phase I jurisdictions (cont)

Area of residence	2017			2018		
	No.	RSE (%)	95% CI	No.	RSE (%)	95% CI
New York						
Bronx County	390	24.6	200–580	420	27.3	190–650
Kings County	500	21.7	290–720	460	26.1	230–700
New York County	340	26.2	170–520	*300	*32.4	*110–*490
Queens County	320	27.1	150–490	*320	*31.4	*120–*510
North Carolina						
Mecklenburg County	270	27.6	120–420	*170	*48.9	*10–*330
Ohio						
Cuyahoga County	*130	*46.3	*10–*260
Franklin County	*200	*38.3	*50–*350	*200	*43.1	*30–*380
Hamilton County	*160	*42.7	*30–*290
Pennsylvania						
Philadelphia County	380	22.2	220–550	390	25.0	200–580
Puerto Rico						
San Juan Municipio ^a
Tennessee						
Shelby County	*220	*30.7	*90–*350	*240	*32	*90–*390
Texas						
Bexar County	310	29.5	130–490	*370	*32.0	*140–*590
Dallas County	790	18.4	510–1,100	810	21.5	470–1,200
Harris County	1,100	15.4	790–1,500	1,200	17.7	770–1,600
Tarrant County	310	29.8	130–480	*260	*38	*70–*450
Travis County	*210	*35.8	*60–*360	*250	*38.6	*60–*440
Washington						
King County	*210	*36.5	*60–*370	*310	*34.6	*100–*520

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Estimates derived by using HIV surveillance and CD4 data for persons aged ≥ 13 years at diagnosis. Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty. Estimates with an RSE of 30%–50% are preceded by an asterisk (*) and should be used with caution because they do not meet the standard of reliability. Estimates with an RSE of >50% are not shown and are replaced by an ellipsis (...).

^a Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: New Jersey and Pennsylvania (excluding Philadelphia County). Areas with incomplete reporting: Arizona, Nevada (2017 only), and Puerto Rico.

Table 2a. Estimated HIV prevalence among persons aged ≥13 years, by selected characteristics, 2017 and 2018—United States

	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. ^a	%	RSE (%)	95% CI
2017							
Sex at birth							
Male	893,800	1.0	875,900–911,600	758,229	84.8	1.0	83.2–86.6
Female	258,700	1.7	250,200–267,100	230,317	89.0	1.7	86.2–92.1
Age at infection (yr)							
13–24	54,400	1.5	52,800–56,100	27,464	50.5	1.5	49.0–52.1
25–34	210,000	0.6	207,300–212,600	148,461	70.7	0.6	69.8–71.6
35–44	221,400	0.5	219,300–223,500	187,660	84.8	0.5	84.0–85.6
45–54	318,200	0.4	316,000–320,400	293,939	92.4	0.4	91.7–93.0
≥55	348,500	0.4	345,700–351,300	331,022	95.0	0.4	94.2–95.8
Race/ethnicity							
American Indian/Alaska Native	3,700	16.7	2,500–4,900	2,958	79.7	18.7	60.0–100
Asian ^b	17,000	7.1	14,600–19,400	14,030	82.6	7.3	72.5–96.0
Black/African American	474,100	1.4	461,300–486,800	405,295	85.5	1.4	83.3–87.9
Hispanic/Latino ^c	266,300	1.9	256,600–276,100	220,585	82.8	1.9	79.9–86.0
Native Hawaiian/other Pacific Islander	*1,000	*30.2	*410–*1,600	*819	*80.7	*46.7	*50.6–*100
White	336,600	1.6	326,200–346,900	297,526	88.4	1.6	85.8–91.2
Multiple races	53,000	3.6	49,300–56,800	46,591	87.8	3.6	82.0–94.6
Transmission category^d							
Male-to-male sexual contact	661,800	1.2	646,600–676,900	553,173	83.6	1.2	81.7–85.5
Injection drug use	126,800	2.6	120,400–133,200	118,416	93.4	2.6	88.9–98.3
Male	74,600	3.5	69,400–79,700	69,360	93.0	3.5	87.0–99.9
Female	52,300	3.7	48,500–56,000	49,056	93.9	3.7	87.5–100
Male-to-male sexual contact and injection drug use	60,600	3.4	56,500–64,600	55,760	92.0	3.4	86.2–98.6
Heterosexual contact ^e	299,800	1.7	290,100–309,500	257,923	86.0	1.7	83.3–88.9
Male	94,800	3.4	88,500–101,000	77,963	82.3	3.4	77.2–88.1
Female	205,000	1.9	197,600–212,500	179,961	87.8	1.9	84.7–91.1
Region of residence							
Northeast	253,800	1.8	244,800–262,800	228,985	90.2	1.8	87.1–93.5
Midwest	140,400	2.5	133,500–147,300	118,040	84.1	2.5	80.1–88.4
South	527,700	1.3	514,100–541,300	445,343	84.4	1.3	82.3–86.6
West	230,600	1.9	221,800–239,300	196,178	85.1	1.9	82.0–88.4
Total^f	1,152,400	0.9	1,132,700–1,172,200	988,546	85.8	0.9	84.3–87.3

Table 2a. Estimated HIV prevalence among persons aged ≥13 years, by selected characteristics, 2017 and 2018—United States (cont)

	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. ^a	%	RSE (%)	95% CI
2018							
Sex at birth							
Male	912,100	1.1	892,000–932,100	777,859	85.3	1.1	83.4–87.2
Female	261,800	1.8	252,400–271,100	234,181	89.5	1.8	86.4–92.8
Age at infection (yr)							
13–24	47,800	1.9	46,000–49,600	26,296	55.1	1.9	53.1–57.2
25–34	216,600	0.7	213,600–219,700	153,228	70.7	0.7	69.8–71.7
35–44	225,200	0.5	222,800–227,500	190,122	84.4	0.5	83.6–85.3
45–54	305,300	0.4	303,000–307,600	282,123	92.4	0.4	91.7–93.1
≥55	379,000	0.4	376,000–382,000	360,271	95.1	0.4	94.3–95.8
Race/ethnicity							
American Indian/Alaska Native	3,900	18.3	2,500–5,300	3,104	80.1	21.1	58.9–100
Asian ^b	17,600	7.8	14,900–20,300	14,922	85.0	8.0	73.7–100
Black/African American	482,900	1.5	468,700–497,200	415,175	86.0	1.5	83.5–88.6
Hispanic/Latino ^c	274,100	2.1	263,000–285,200	228,379	83.3	2.1	80.1–86.8
Native Hawaiian/other Pacific Islander	*1,100	*33.6	*360–*1,800
White	340,700	1.7	329,200–352,100	302,340	88.7	1.7	85.9–91.8
Multiple races	52,900	4.0	48,700–57,100	46,503	87.9	4.0	81.5–95.4
Transmission category^d							
Male-to-male sexual contact	679,800	1.3	662,700–696,900	571,934	84.1	1.3	82.1–86.3
Injection drug use	125,900	2.8	118,900–132,800	117,710	93.5	2.8	88.6–99.0
Male	73,900	3.9	68,300–79,500	68,794	93.1	3.9	86.6–100
Female	52,000	4.0	47,900–56,100	48,916	94.1	4.1	87.2–100
Male-to-male sexual contact and injection drug use	60,600	3.7	56,100–65,000	55,781	92.1	3.8	85.8–99.4
Heterosexual contact ^e	304,200	1.8	293,400–315,000	263,355	86.6	1.8	83.6–89.8
Male	95,800	3.7	88,800–102,700	79,401	82.9	3.7	77.3–89.4
Female	208,400	2.0	200,100–216,700	183,955	88.3	2.0	84.9–91.9
Region of residence							
Northeast	255,600	2.0	245,700–265,500	231,282	90.5	2.0	87.1–94.1
Midwest	143,200	2.7	135,500–150,900	121,147	84.6	2.7	80.3–89.4
South	539,600	1.4	524,300–554,900	457,974	84.9	1.4	82.5–87.3
West	235,400	2.1	225,600–245,300	201,637	85.6	2.1	82.2–89.4
Total^f	1,173,900	1.0	1,151,700–1,196,000	1,012,040	86.2	1.0	84.6–87.9

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Estimates for the year 2018 data are preliminary and based on deaths reported to CDC as of December 2019. Estimates derived by using HIV surveillance and CD4 data for persons aged ≥13 years at diagnosis. Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty. Estimates with an RSE of 30%–50% are preceded by an asterisk (*) and should be used with caution because they do not meet the standard of reliability. Estimates with an RSE of >50% are not shown and are replaced by an ellipsis (...).

^a Reported to the National HIV Surveillance System.

^b Includes Asian/Pacific Islander legacy cases.

^c Hispanics/Latinos can be of any race.

^d Data by transmission category have been statistically adjusted to account for missing risk-factor information.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes persons with HIV infection attributed to hemophilia or blood transfusion, or whose risk factor was not reported or not identified.

Table 2b. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017 and 2018—United States and Puerto Rico

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			2017	Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI		No. ^a	%	RSE (%)	95% CI
Alabama ^b	15,700	7.7	13,300–18,100		12,940	82.3	7.9	71.5–97.0
Alaska	*810	*30.5	*320–*1,300		*703	*87.0	*47.7	*54.4–*100
Arizona ^c	19,000	6.8	16,400–21,500		15,779	83.2	7.0	73.4–96.1
Arkansas ^c	6,800	11.9	5,200–8,400		5,561	81.4	12.6	66.0–100
California	146,700	2.4	139,900–153,500		127,569	87.0	2.4	83.1–91.2
Colorado	14,400	7.1	12,400–16,300		12,137	84.6	7.3	74.2–98.3
Connecticut ^c	11,400	8.3	9,500–13,200		10,157	89.2	8.5	76.7–100
Delaware	3,800	15.4	2,600–4,900		3,233	86.1	16.9	66.2–100
District of Columbia	15,100	7.1	13,000–17,300		14,189	93.7	7.3	82.2–100
Florida	124,100	2.6	117,700–130,500		107,258	86.4	2.6	82.2–91.1
Georgia	63,400	3.7	58,800–68,000		52,338	82.6	3.7	77.0–89.0
Hawaii	2,700	17.2	1,800–3,600		2,470	90.7	19.4	67.8–100
Idaho ^c	1,300	27.6	600–2,000		*1,113	*85.1	*39.2	*55.2–*100
Illinois	40,300	4.6	36,700–44,000		34,703	86.0	4.7	78.8–94.6
Indiana	13,500	8.6	11,200–15,700		10,991	81.7	8.8	69.9–98.2
Iowa	3,300	16.3	2,200–4,300		2,647	80.9	18.2	61.2–100
Kansas ^c	3,600	16.5	2,500–4,800		2,967	81.7	18.5	61.7–100
Kentucky ^c	8,600	10.2	6,900–10,400		7,028	81.3	10.7	67.7–100
Louisiana	24,600	6.4	21,500–27,700		20,229	82.3	6.5	73.1–94.1
Maine	1,800	20.6	1,100–2,500		1,545	85.2	24.7	60.6–100
Maryland	36,500	4.7	33,100–39,900		32,175	88.2	4.8	80.7–97.2
Massachusetts	22,400	5.8	19,900–24,900		20,106	89.7	5.8	80.6–100
Michigan	18,500	7.3	15,900–21,200		15,475	83.6	7.5	73.1–97.6
Minnesota	9,600	8.7	7,900–11,200		8,172	85.3	9.0	72.9–100
Mississippi	11,100	10.0	8,900–13,300		9,235	83.1	10.4	69.4–100
Missouri	14,300	7.5	12,200–16,400		12,210	85.6	7.7	74.7–100
Montana	*740	*31.2	*290–*1,200		*613	*83.1	*50.0	*51.6–*100
Nebraska	2,500	18.3	1,600–3,500		2,100	82.6	21.1	60.7–100
Nevada ^c	12,200	8.6	10,200–14,300		9,503	77.6	8.9	66.4–93.5
New Hampshire	1,400	23.0	770–2,000		1,168	83.4	28.9	57.4–100
New Jersey ^c	38,200	5.2	34,300–42,100		34,212	89.6	5.2	81.3–99.7
New Mexico	4,100	14.0	3,000–5,200		3,388	82.5	15.1	64.7–100
New York	136,200	2.4	129,900–142,500		123,702	90.8	2.4	86.8–95.2
North Carolina	35,500	4.7	32,200–38,800		30,572	86.2	4.8	78.9–95.0
North Dakota	*630	*48.8	*30–*1,200	
Ohio	26,100	5.9	23,100–29,100		21,696	83.3	6.0	74.7–94.1
Oklahoma ^b	7,200	11.3	5,600–8,800		5,983	83.0	11.9	67.9–100
Oregon	8,000	9.8	6,400–9,500		6,826	85.7	10.2	71.9–100
Pennsylvania ^c	39,200	5.1	35,300–43,200		34,916	89.0	5.2	80.9–99.0
Puerto Rico ^c	17,100	7.9	14,400–19,800		15,706	91.8	8.1	79.5–100
Rhode Island	2,900	16.4	2,000–3,800		2,501	86.6	18.3	65.5–100
South Carolina ^b	20,100	6.9	17,400–22,900		16,668	82.8	7.0	72.9–95.7
South Dakota	*730	*35.4	*220–*1,200	
Tennessee	19,800	6.5	17,200–22,300		16,491	83.4	6.7	73.9–95.7
Texas	106,700	2.9	100,600–112,900		87,465	81.9	2.9	77.5–86.9
Utah	3,400	15.4	2,400–4,400		2,720	80.0	16.9	61.5–100
Vermont ^c	*810	*36.4	*230–*1,400	
Virginia	25,700	5.6	22,900–28,500		22,199	86.3	5.7	77.8–97.0
Washington	15,200	7.3	13,000–17,400		13,040	85.9	7.5	75.2–100
West Virginia	2,200	21.1	1,300–3,100		1,779	80.3	25.5	56.8–100
Wisconsin	7,200	10.7	5,700–8,700		6,116	85.1	11.2	70.4–100
Wyoming	*400	*47.0	*30–*770	

Table 2b. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017 and 2018—United States and Puerto Rico (cont)

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. ^a	%	RSE (%)	95% CI
2018							
Alabama ^b	16,200	8.4	13,500–18,900	13,478	83.2	8.6	71.5–99.7
Alaska	*820	*33.3	*280–*1,400
Arizona ^c	19,600	7.6	16,700–22,500	16,445	84.0	7.8	73.1–98.6
Arkansas ^c	7,000	13.1	5,200–8,800	5,674	81.2	14.1	64.5–100
California	149,500	2.6	141,900–157,200	130,259	87.1	2.6	82.9–91.8
Colorado	14,600	7.8	12,400–16,900	12,604	86.3	8.0	74.8–100
Connecticut ^c	11,400	9.0	9,400–13,400	10,316	90.5	9.3	76.9–100
Delaware	3,800	16.9	2,500–5,000	3,269	86.2	19.0	64.8–100
District of Columbia	15,100	7.7	12,800–17,400	14,067	93.0	7.9	80.8–100
Florida	126,400	2.9	119,300–133,600	109,500	86.6	2.9	82.0–91.8
Georgia	65,200	4.1	59,900–70,400	54,117	83.1	4.1	76.9–90.3
Hawaii	2,700	18.9	1,700–3,800	2,421	88.2	21.9	64.4–100
Idaho ^c	*1,400	*31.7	*510–*2,200
Illinois	41,200	5.1	37,100–45,300	35,512	86.2	5.1	78.3–95.7
Indiana	13,900	9.5	11,300–16,400	11,377	82.1	9.8	69.2–100
Iowa	3,400	18.3	2,200–4,600	2,763	81.7	21.0	60.2–100
Kansas ^c	3,700	18.4	2,400–5,100	3,047	82.0	21.1	60.3–100
Kentucky ^c	9,000	11.3	7,000–10,900	7,274	81.2	11.9	66.4–100
Louisiana	25,300	7.1	21,800–28,800	20,739	82.0	7.2	72.0–95.2
Maine	1,800	22.6	1,000–2,700	1,590	86.5	28.1	60.0–100
Maryland	36,800	5.1	33,100–40,500	32,652	88.8	5.2	80.7–98.8
Massachusetts	22,900	6.3	20,100–25,700	20,413	89.2	6.4	79.4–100
Michigan	18,900	8.1	15,900–21,900	15,798	83.6	8.3	72.2–99.3
Minnesota	9,800	9.6	8,000–11,700	8,462	86.3	10.0	72.6–100
Mississippi	11,300	11.2	8,800–13,800	9,355	82.5	11.8	67.6–100
Missouri	14,500	8.3	12,100–16,800	12,529	86.5	8.5	74.4–100
Montana	*750	*34.5	*240–*1,300
Nebraska	2,600	20.1	1,500–3,600	2,145	84.0	23.8	60.2–100
Nevada ^c	12,700	9.7	10,300–15,100	10,138	79.7	10.0	67.0–98.4
New Hampshire	1,400	24.9	720–2,100	*1,238	*88.3	*32.8	*59.3–*100
New Jersey ^c	38,500	5.7	34,200–42,800	34,360	89.3	5.8	80.3–100
New Mexico	4,200	15.4	2,900–5,500	3,560	84.7	17.0	65.0–100
New York	136,700	2.6	129,800–143,600	124,555	91.1	2.6	86.8–95.9
North Carolina	36,000	5.2	32,300–39,600	31,514	87.6	5.2	79.5–97.5
North Dakota
Ohio	26,600	6.4	23,200–29,900	22,222	83.6	6.6	74.2–95.7
Oklahoma ^b	7,500	12.5	5,600–9,300	6,194	83.1	13.4	66.7–100
Oregon	8,100	10.8	6,400–9,800	7,006	86.6	11.4	71.4–100
Pennsylvania ^c	39,500	5.7	35,100–44,000	35,559	89.9	5.8	80.9–100
Puerto Rico ^c	17,100	8.5	14,300–20,000	15,596	91.1	8.8	78.0–100
Rhode Island	2,900	17.8	1,900–3,900	2,553	87.8	20.2	65.1–100
South Carolina ^b	20,600	7.6	17,500–23,700	17,222	83.5	7.8	72.6–98.2
South Dakota	*760	*40.4	*160–*1,400
Tennessee	20,000	7.2	17,200–22,900	17,183	85.7	7.3	75.2–99.7
Texas	110,100	3.2	103,200–117,100	91,045	82.7	3.2	77.8–88.2
Utah	3,500	16.9	2,300–4,600	2,897	83.3	19.0	62.6–100
Vermont ^c	*820	*40.1	*170–*1,500
Virginia	26,200	6.2	23,100–29,400	22,819	86.9	6.3	77.6–98.9
Washington	15,500	8.1	13,000–18,000	13,472	86.9	8.3	75.0–100
West Virginia	2,300	23.7	1,200–3,300	*1,872	*82.5	*30.2	*56.4–*100
Wisconsin	7,300	11.8	5,600–9,000	6,253	85.9	12.4	69.8–100
Wyoming

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Estimates for the year 2018 data are preliminary and based on deaths reported to CDC as of December 2019. Estimates derived by using HIV surveillance and CD4 data for persons aged ≥13 years at diagnosis. Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty. Estimates with an RSE of 30%–50% are preceded by an asterisk (*) and should be used with caution because they do not meet the standard of reliability. Estimates with an RSE of >50% are not shown and are replaced by an ellipsis (...).

^a Reported to the National HIV Surveillance System.

^b Estimates should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2018.

^c Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: Idaho, New Jersey, Pennsylvania. Areas with incomplete reporting: Arizona, Arkansas, Connecticut (2018 only), Kansas, Kentucky, Nevada (2017 only), Vermont, and Puerto Rico.

Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017 and 2018—Ending the HIV Epidemic Phase I jurisdictions

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. ^a	%	RSE (%)	95% CI
2017							
Arizona							
Maricopa County ^b	12,900	8.1	10,900–15,000	10,798	83.7	8.3	72.2–99.5
California							
Alameda County	6,800	11.0	5,300–8,300	5,845	85.7	11.6	70.5–100
Los Angeles County	54,000	3.8	50,000–58,100	48,364	89.5	3.9	83.2–96.8
Orange County	8,000	10.2	6,400–9,600	6,738	84.2	10.6	70.2–100
Riverside County	10,100	8.0	8,500–11,700	8,478	84.0	8.3	72.6–99.8
Sacramento County	5,000	13.2	3,700–6,200	4,154	83.9	14.1	66.6–100
San Bernardino County	5,300	13.0	3,900–6,600	4,077	77.4	13.9	61.7–100
San Diego County	15,100	7.1	13,000–17,300	12,871	85.0	7.3	74.6–98.9
San Francisco County	12,900	8.0	10,900–14,900	12,290	95.2	8.2	82.3–100
District of Columbia	15,100	7.1	13,000–17,300	14,189	93.7	7.3	82.2–100
Florida							
Broward County	21,500	6.0	19,000–24,000	18,936	88.0	6.1	78.7–99.7
Duval County	7,100	11.1	5,600–8,700	5,818	81.7	11.6	67.1–100
Hillsborough County	7,700	10.5	6,100–9,300	6,561	85.2	11.0	70.7–100
Miami-Dade County	28,900	5.6	25,700–32,000	25,653	88.8	5.6	80.1–99.7
Orange County	9,600	9.3	7,900–11,400	8,231	85.4	9.7	72.2–100
Palm Beach County	8,800	9.8	7,100–10,500	7,706	87.7	10.1	73.6–100
Pinellas County	5,000	12.9	3,800–6,300	4,410	87.8	13.8	70.0–100
Georgia							
Cobb County	3,700	14.8	2,600–4,700	2,994	81.5	16.1	63.2–100
DeKalb County	9,700	9.1	7,900–11,400	8,103	83.8	9.4	71.2–100
Fulton County	17,500	7.0	15,000–19,900	14,267	81.7	7.2	71.8–94.8
Gwinnett County	3,300	15.0	2,300–4,200	2,721	83.3	16.4	64.4–100
Illinois							
Cook County	28,300	5.6	25,200–31,400	24,724	87.3	5.6	78.7–98.1
Indiana							
Marion County	5,500	13.1	4,100–6,900	4,502	82.4	14.0	65.5–100
Louisiana							
East Baton Rouge Parish	4,500	14.2	3,300–5,800	3,808	83.9	15.4	65.6–100
Orleans Parish	5,600	13.0	4,100–7,000	4,798	86.1	13.9	68.6–100
Maryland							
Baltimore City	10,300	9.4	8,400–12,200	10,053	97.7	9.7	82.5–100
Montgomery County	3,900	14.1	2,800–5,000	3,320	84.2	15.3	65.9–100
Prince George's County	6,600	11.6	5,100–8,100	5,897	89.9	12.3	73.2–100
Massachusetts							
Suffolk County	6,200	11.1	4,900–7,600	5,712	92.0	11.6	75.6–100
Michigan							
Wayne County	7,800	11.4	6,100–9,600	6,363	81.4	12.1	66.5–100
Nevada							
Clark County ^b	10,300	9.3	8,500–12,200	7,991	77.3	9.7	65.3–94.6
New Jersey							
Essex County ^b	9,800	10.5	7,800–11,900	8,975	91.2	11.0	75.6–100
Hudson County ^b	5,400	13.6	3,900–6,800	4,811	89.7	14.7	70.8–100

Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017 and 2018—Ending the HIV Epidemic Phase I jurisdictions (*cont*)

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. ^a	%	RSE (%)	95% CI
New York							
Bronx County	29,300	4.9	26,500–32,100	26,610	90.8	4.9	82.9–100
Kings County	28,400	5.3	25,400–31,300	25,736	90.8	5.3	82.3–100
New York County	29,100	5.1	26,200–32,000	26,770	92.1	5.2	83.7–100
Queens County	17,000	6.5	14,800–19,200	15,401	90.6	6.6	80.3–100
North Carolina							
Mecklenburg County	6,500	11.1	5,100–7,900	5,642	86.6	11.6	71.1–100
Ohio							
Cuyahoga County	5,400	12.6	4,100–6,800	4,583	84.6	13.4	67.8–100
Franklin County	5,600	12.5	4,200–7,000	4,749	84.5	13.4	67.8–100
Hamilton County	3,500	16.3	2,400–4,600	2,888	82.8	18.2	62.7–100
Pennsylvania							
Philadelphia County	18,400	6.7	16,000–20,800	16,813	91.3	6.8	80.7–100
Puerto Rico							
San Juan Municipio ^b	3,400	18.9	2,100–4,600	3,170	93.6	22.0	68.2–100
Tennessee							
Shelby County	7,000	11.3	5,500–8,600	6,031	85.8	11.9	70.2–100
Texas							
Bexar County	7,300	11.2	5,700–8,900	6,083	83.5	11.8	68.4–100
Dallas County	20,900	6.5	18,300–23,600	17,348	83.0	6.6	73.6–95.1
Harris County	29,600	5.6	26,400–32,800	24,632	83.2	5.7	75.0–93.4
Tarrant County	6,600	11.6	5,100–8,100	5,435	82.6	12.2	67.3–100
Travis County	5,800	12.4	4,400–7,300	4,714	80.7	13.2	64.9–100
Washington							
King County	7,600	10.3	6,100–9,100	6,763	89.2	10.7	74.3–100

Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017 and 2018—Ending the HIV Epidemic Phase I jurisdictions (cont)

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. ^a	%	RSE (%)	95% CI
2018							
Arizona							
Maricopa County ^b	13,300	9.0	11,000–15,700	11,246	84.4	9.3	71.8–100
California							
Alameda County	6,900	12.0	5,300–8,600	6,013	86.8	12.7	70.2–100
Los Angeles County	54,900	4.2	50,300–59,400	49,184	89.7	4.2	82.9–97.7
Orange County	8,200	11.2	6,400–10,000	6,836	83.6	11.7	68.5–100
Riverside County	10,200	8.9	8,400–12,000	8,989	88.1	9.2	74.9–100
Sacramento County	5,100	14.4	3,600–6,500	4,249	83.9	15.6	65.4–100
San Bernardino County	5,500	14.3	3,900–7,000	4,426	80.9	15.5	63.2–100
San Diego County	15,500	7.8	13,100–17,800	13,048	84.4	8.0	73.2–99.7
San Francisco County	12,900	8.6	10,700–15,100	12,128	94.0	8.9	80.4–100
District of Columbia	15,100	7.7	12,800–17,400	14,067	93.0	7.9	80.8–100
Florida							
Broward County	21,900	6.5	19,100–24,600	19,249	88.1	6.6	78.1–100
Duval County	7,200	12.1	5,500–8,900	6,006	83.3	12.8	67.4–100
Hillsborough County	7,800	11.5	6,100–9,600	6,757	86.2	12.1	70.3–100
Miami-Dade County	29,600	6.0	26,100–33,100	26,015	87.9	6.1	78.6–99.7
Orange County	10,000	10.2	8,000–12,000	8,514	85.4	10.6	71.2–100
Palm Beach County	8,900	10.6	7,000–10,700	7,790	87.9	11.1	72.8–100
Pinellas County	5,100	14.1	3,700–6,500	4,427	87.5	15.2	68.5–100
Georgia							
Cobb County	3,800	16.2	2,600–5,000	3,130	83.0	18.0	63.0–100
DeKalb County	9,900	10.0	8,000–11,900	8,371	84.2	10.4	70.4–100
Fulton County	18,000	7.7	15,200–20,700	15,044	83.7	7.9	72.7–98.7
Gwinnett County	3,400	16.5	2,300–4,400	2,829	84.1	18.4	63.6–100
Illinois							
Cook County	28,900	6.1	25,400–32,300	24,970	86.5	6.2	77.3–98.3
Indiana							
Marion County	5,600	14.4	4,000–7,200	4,645	82.9	15.7	64.6–100
Louisiana							
East Baton Rouge Parish	4,700	15.6	3,200–6,100	3,888	83.6	17.3	63.9–100
Orleans Parish	5,700	14.2	4,100–7,300	4,893	86.3	15.5	67.5–100
Maryland							
Baltimore City	10,100	10.2	8,100–12,200	9,317	91.9	10.7	76.5–100
Montgomery County	4,000	15.3	2,800–5,200	3,545	88.8	16.8	68.4–100
Prince George's County	6,800	12.6	5,100–8,400	5,762	85.3	13.4	68.4–100
Massachusetts							
Suffolk County	6,300	12.0	4,800–7,800	5,679	90.3	12.7	73.1–100
Michigan							
Wayne County	8,000	12.6	6,000–9,900	6,673	83.7	13.4	67.2–100
Nevada							
Clark County ^b	10,800	10.4	8,600–13,000	8,541	79.3	10.9	65.8–99.7
New Jersey							
Essex County ^b	9,900	11.5	7,600–12,100	8,952	90.8	12.1	74.2–100
Hudson County ^b	5,500	14.9	3,900–7,100	4,821	88.3	16.3	68.3–100

Table 2c. Estimated HIV prevalence among persons aged ≥13 years, by area of residence, 2017 and 2018—Ending the HIV Epidemic Phase I jurisdictions (cont)

Area of residence	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE (%)	95% CI	No. ^a	%	RSE (%)	95% CI
New York							
Bronx County	29,300	5.3	26,200–32,300	26,849	91.7	5.4	83.1–100
Kings County	28,400	5.7	25,200–31,600	25,939	91.2	5.8	82.1–100
New York County	29,100	5.5	26,000–32,300	26,790	91.9	5.6	83.0–100
Queens County	17,200	7.1	14,800–19,600	15,620	90.6	7.2	79.6–100
North Carolina							
Mecklenburg County	6,600	12.1	5,000–8,200	5,831	88.1	12.8	71.2–100
Ohio							
Cuyahoga County	5,500	13.7	4,000–7,000	4,669	85.2	14.8	67.1–100
Franklin County	5,800	13.8	4,200–7,300	4,804	83.4	14.9	65.6–100
Hamilton County	3,600	17.9	2,300–4,800	2,923	82.1	20.5	60.7–100
Pennsylvania							
Philadelphia County	18,500	7.2	15,900–21,100	16,679	90.3	7.3	79.2–100
Puerto Rico							
San Juan Municipio ^b	3,400	20.3	2,000–4,700	3,213	95.1	24.2	68.0–100
Tennessee							
Shelby County	7,200	12.2	5,400–8,900	6,156	86.0	13.0	69.4–100
Texas							
Bexar County	7,600	12.3	5,800–9,400	6,266	82.5	13.1	66.4–100
Dallas County	21,500	7.1	18,500–24,500	18,032	83.9	7.3	73.6–97.5
Harris County	30,400	6.1	26,700–34,000	25,433	83.8	6.2	74.8–95.2
Tarrant County	6,800	12.8	5,100–8,500	5,662	83.8	13.6	67.0–100
Travis County	6,100	13.7	4,400–7,700	4,902	80.8	14.7	63.7–100
Washington							
King County	7,800	11.4	6,000–9,500	6,844	88.1	12.0	72.1–100

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. Estimates for the year 2018 data are preliminary and based on deaths reported to CDC as of December 2019.

Estimates derived by using HIV surveillance data and CD4 data for persons aged ≥13 years at diagnosis.

Estimates rounded to the nearest 100 for estimates of >1,000 and to the nearest 10 for estimates of ≤1,000 to reflect model uncertainty.

Estimates with an RSE of 30%–50% are preceded by an asterisk (*) and should be used with caution because they do not meet the standard of reliability.

Estimates with an RSE of >50% are not shown and are replaced by an ellipsis (...).

^a Reported to the National HIV Surveillance System.

^b Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: New Jersey and Pennsylvania (excluding Philadelphia County). Areas with incomplete reporting: Arizona, Nevada (2017 only), and Puerto Rico.

Table 3a. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, 2017 and 2018—United States

	2017 Total No.	2018 Total No.
Gender		
Male	30,488	29,753
Female	7,268	7,063
Transgender male-to-female ^a	549	553
Transgender female-to-male ^a	33	47
Additional gender identity ^b	13	12
Age at infection (yr)		
13–24	8,273	7,817
25–34	13,376	13,355
35–44	7,267	7,196
45–54	5,604	5,294
≥ 55	3,831	3,766
Race/ethnicity		
American Indian/Alaska Native	208	186
Asian	937	871
Black/African American	16,460	15,994
Hispanic/Latino ^c	9,773	9,811
Native Hawaiian/other Pacific Islander	52	66
White	9,804	9,557
Multiple races	1,117	943
Transmission category^d		
Male-to-male sexual contact	25,455	24,669
Injection drug use		
Male	1,308	1,408
Female	1,063	1,056
Male-to-male sexual contact and injection drug use	1,383	1,361
Heterosexual contact ^e		
Male	2,871	2,845
Female	6,192	6,014
Other ^f		
Male	33	35
Female	46	40
Region of residence^g		
Northeast	5,988	5,573
Midwest	5,088	4,921
South	19,658	19,422
West	7,617	7,512
Total	38,351	37,428

^a “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^c Hispanics/Latinos can be of any race.

^d Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and may include transgender persons.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

^g Data are based on residence at time of diagnosis of HIV infection.

Table 3b. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, 2017 and 2018—United States and 6 dependent areas

	2017 Total No.	2018 Total No.
Gender		
Male	30,855	30,125
Female	7,362	7,143
Transgender male-to-female ^a	551	554
Transgender female-to-male ^a	33	47
Additional gender identity ^b	13	12
Age at infection (yr)		
13–24	8,350	7,891
25–34	13,504	13,491
35–44	7,357	7,275
45–54	5,697	5,389
≥ 55	3,906	3,835
Race/ethnicity		
American Indian/Alaska Native	208	186
Asian	940	875
Black/African American	16,464	16,002
Hispanic/Latino ^c	10,222	10,246
Native Hawaiian/other Pacific Islander	55	68
White	9,807	9,560
Multiple races	1,118	944
Transmission category^d		
Male-to-male sexual contact	25,693	24,933
Injection drug use		
Male	1,342	1,434
Female	1,072	1,058
Male-to-male sexual contact and injection drug use	1,395	1,372
Heterosexual contact ^e		
Male	2,956	2,916
Female	6,276	6,092
Other ^f		
Male	33	35
Female	46	40
Region of residence^g		
Northeast	5,988	5,573
Midwest	5,088	4,921
South	19,658	19,422
West	7,617	7,512
U.S. dependent areas	463	453
Total	38,814	37,881

^a "Transgender male-to-female" includes individuals who were assigned "male" sex at birth but have ever identified as "female" gender. "Transgender female-to-male" includes individuals who were assigned "female" sex at birth but have ever identified as "male" gender.

^b Additional gender identity examples include "bigender," "gender queer," and "two-spirit."

^c Hispanics/Latinos can be of any race.

^d Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total. Data presented based on sex at birth and may include transgender persons.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.

^g Data are based on residence at time of diagnosis of HIV infection.

Table 3c. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, 2017 and 2018—United States and 6 dependent areas

Area of residence	2017 Total No.	2018 Total No.
Alabama	649	607
Alaska	29	23
Arizona	725	759
Arkansas	288	281
California	4,878	4,712
Colorado	438	399
Connecticut	274	258
Delaware	126	92
District of Columbia	313	275
Florida	4,555	4,573
Georgia	2,588	2,501
Hawaii	77	70
Idaho	46	37
Illinois	1,363	1,361
Indiana	517	512
Iowa	126	115
Kansas	120	155
Kentucky	364	372
Louisiana	1,002	972
Maine	29	30
Maryland	1,024	996
Massachusetts	600	650
Michigan	776	716
Minnesota	275	288
Mississippi	428	477
Missouri	504	447
Montana	31	23
Nebraska	88	79
Nevada	493	503
New Hampshire	33	38
New Jersey	1,121	1,025
New Mexico	140	122
New York	2,731	2,456
North Carolina	1,299	1,187
North Dakota	37	36
Ohio	982	977
Oklahoma	300	280
Oregon	203	229
Pennsylvania	1,096	1,023
Rhode Island	84	75
South Carolina	709	715
South Dakota	39	29
Tennessee	720	762
Texas	4,354	4,388
Utah	114	119
Vermont	20	18
Virginia	863	858
Washington	433	504
West Virginia	76	86
Wisconsin	261	206
Wyoming	10	12
Subtotal	38,351	37,428
U.S. dependent areas		
American Samoa	0	0
Guam	6	7
Northern Mariana Islands	1	1
Puerto Rico	448	436
Republic of Palau	0	0
U.S. Virgin Islands	8	9
Subtotal	463	453
Total	38,814	37,881

Note. Data are based on residence at time of diagnosis of HIV infection.

Table 3d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, 2017 and 2018—Ending the HIV Epidemic Phase I jurisdictions

Area of residence	2017 Total No.	2018 Total No.
Arizona		
Maricopa County	494	535
California		
Alameda County	204	198
Los Angeles County	1,799	1,690
Orange County	312	286
Riverside County	273	257
Sacramento County	170	156
San Bernardino County	253	274
San Diego County	414	378
San Francisco County	244	237
District of Columbia	313	275
Florida		
Broward County	671	626
Duval County	300	274
Hillsborough County	300	301
Miami-Dade County	1,141	1,177
Orange County	461	464
Palm Beach County	289	284
Pinellas County	164	175
Georgia		
Cobb County	153	153
DeKalb County	364	362
Fulton County	618	605
Gwinnett County	173	151
Illinois		
Cook County	978	970
Indiana		
Marion County	226	205
Louisiana		
East Baton Rouge Parish	166	178
Orleans Parish	186	179
Maryland		
Baltimore City	238	231
Montgomery County	162	126
Prince George's County	309	308
Massachusetts		
Suffolk County	159	147
Michigan		
Wayne County	325	300
Nevada		
Clark County	444	450
New Jersey		
Essex County	313	263
Hudson County	164	161

Table 3d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, 2017 and 2018—Ending the HIV Epidemic Phase I jurisdictions (*cont*)

Area of residence	2017 Total No.	2018 Total No.
New York		
Bronx County	506	447
Kings County	630	548
New York County	396	371
Queens County	431	411
North Carolina		
Mecklenburg County	269	242
Ohio		
Cuyahoga County	148	149
Franklin County	222	194
Hamilton County	187	184
Pennsylvania		
Philadelphia County	498	442
Puerto Rico		
San Juan Municipio	110	104
Tennessee		
Shelby County	259	303
Texas		
Bexar County	348	325
Dallas County	815	785
Harris County	1,100	1,199
Tarrant County	303	275
Travis County	210	189
Washington		
King County	210	292

Note. Data are based on residence at time of diagnosis of HIV infection.

Table 4a. Linkage to HIV medical care within 1 month after HIV diagnosis during 2017, among persons aged ≥13 years, by selected characteristics—41 states and the District of Columbia

	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
Gender					
Male	27,111	21,071	77.7	6,040	22.3
Female	6,437	5,032	78.2	1,405	21.8
Transgender male-to-female ^a	488	375	76.8	113	23.2
Transgender female-to-male ^a	29	27	93.1	2	6.9
Additional gender identity ^b	13	12	92.3	1	7.7
Age at diagnosis (yr)					
13–24	7,388	5,514	74.6	1,874	25.4
25–34	11,916	9,143	76.7	2,773	23.3
35–44	6,455	5,116	79.3	1,339	20.7
45–54	4,939	4,002	81.0	937	19.0
≥55	3,380	2,742	81.1	638	18.9
Race/ethnicity					
American Indian/Alaska Native	156	130	83.3	26	16.7
Asian	843	684	81.1	159	18.9
Black/African American	14,854	11,180	75.3	3,674	24.7
Hispanic/Latino ^c	8,677	6,803	78.4	1,874	21.6
Native Hawaiian/other Pacific Islander	41	33	80.5	8	19.5
White	8,478	6,864	81.0	1,614	19.0
Multiple races	1,029	823	80.0	206	20.0
Transmission category ^d					
Male-to-male sexual contact	22,763	17,766	78.0	4,997	22.0
Injection drug use					
Male	1,076	820	76.3	255	23.7
Female	901	685	75.9	217	24.1
Male-to-male sexual contact and injection drug use	1,191	889	74.6	302	25.4
Heterosexual contact ^e					
Male	2,553	1,959	76.7	595	23.3
Female	5,527	4,342	78.6	1,185	21.4
Total ^f	34,078	26,517	77.8	7,561	22.2

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data not provided for jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or for areas with incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Kansas, Kentucky, Nevada, Puerto Rico, and Vermont.

^a “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^c Hispanics/Latinos can be of any race.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and may include transgender persons.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified.

Table 4b. Linkage to HIV medical care within 1 month after HIV diagnosis during 2017, among persons aged ≥13 years, by area of residence—41 states and the District of Columbia

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
Alabama	649	499	76.9	150	23.1
Alaska	29	28	96.6	1	3.4
California	4,878	3,624	74.3	1,254	25.7
Colorado	438	369	84.2	69	15.8
Connecticut	274	229	83.6	45	16.4
Delaware	126	108	85.7	18	14.3
District of Columbia	313	249	79.6	64	20.4
Florida	4,555	3,537	77.7	1,018	22.3
Georgia	2,588	1,975	76.3	613	23.7
Hawaii	77	66	85.7	11	14.3
Illinois	1,363	1,115	81.8	248	18.2
Indiana	517	349	67.5	168	32.5
Iowa	126	115	91.3	11	8.7
Louisiana	1,002	792	79.0	210	21.0
Maine	29	27	93.1	2	6.9
Maryland	1,024	872	85.2	152	14.8
Massachusetts	600	524	87.3	76	12.7
Michigan	776	642	82.7	134	17.3
Minnesota	275	241	87.6	34	12.4
Mississippi	428	301	70.3	127	29.7
Missouri	504	364	72.2	140	27.8
Montana	31	27	87.1	4	12.9
Nebraska	88	69	78.4	19	21.6
New Hampshire	33	27	81.8	6	18.2
New Mexico	140	117	83.6	23	16.4
New York	2,731	2,308	84.5	423	15.5
North Carolina	1,299	977	75.2	322	24.8
North Dakota	37	33	89.2	4	10.8
Ohio	982	818	83.3	164	16.7
Oklahoma	300	203	67.7	97	32.3
Oregon	203	160	78.8	43	21.2
Rhode Island	84	77	91.7	7	8.3
South Carolina	709	603	85.0	106	15.0
South Dakota	39	34	87.2	5	12.8
Tennessee	720	438	60.8	282	39.2
Texas	4,354	3,157	72.5	1,197	27.5
Utah	114	104	91.2	10	8.8
Virginia	863	656	76.0	207	24.0
Washington	433	397	91.7	36	8.3
West Virginia	76	59	77.6	17	22.4
Wisconsin	261	218	83.5	43	16.5
Wyoming	10	9	90.0	1	10.0
Total	34,078	26,517	77.8	7,561	22.2

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Kansas, Kentucky, Nevada, Puerto Rico, and Vermont.

Table 4c. Linkage to HIV medical care within 1 month after HIV diagnosis during 2017, among persons aged ≥ 13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
California					
Alameda County	204	175	85.8	29	14.2
Los Angeles County	1,799	1,257	69.9	542	30.1
Orange County	312	240	76.9	72	23.1
Riverside County	273	206	75.5	67	24.5
Sacramento County	170	142	83.5	28	16.5
San Bernardino County	253	166	65.6	87	34.4
San Diego County	414	314	75.8	100	24.2
San Francisco County	244	206	84.4	38	15.6
District of Columbia	313	249	79.6	64	20.4
Florida					
Broward County	671	541	80.6	130	19.4
Duval County	300	211	70.3	89	29.7
Hillsborough County	300	229	76.3	71	23.7
Miami-Dade County	1,141	925	81.1	216	18.9
Orange County	461	325	70.5	136	29.5
Palm Beach County	289	220	76.1	69	23.9
Pinellas County	164	124	75.6	40	24.4
Georgia					
Cobb County	153	125	81.7	28	18.3
DeKalb County	364	276	75.8	88	24.2
Fulton County	618	493	79.8	125	20.2
Gwinnett County	173	131	75.7	42	24.3
Illinois					
Cook County	978	801	81.9	177	18.1
Indiana					
Marion County	226	154	68.1	72	31.9
Louisiana					
East Baton Rouge Parish	166	134	80.7	32	19.3
Orleans Parish	186	152	81.7	34	18.3
Maryland					
Baltimore City	238	200	84.0	38	16.0
Montgomery County	162	129	79.6	33	20.4
Prince George's County	309	271	87.7	38	12.3
Massachusetts					
Suffolk County	159	140	88.1	19	11.9
Michigan					
Wayne County	325	262	80.6	63	19.4
New York					
Bronx County	506	423	83.6	83	16.4
Kings County	630	536	85.1	94	14.9
New York County	396	337	85.1	59	14.9
Queens County	431	365	84.7	66	15.3

Table 4c. Linkage to HIV medical care within 1 month after HIV diagnosis during 2017, among persons aged ≥ 13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*cont*)

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
North Carolina					
Mecklenburg County	269	192	71.4	77	28.6
Ohio					
Cuyahoga County	148	127	85.8	21	14.2
Franklin County	222	193	86.9	29	13.1
Hamilton County	187	160	85.6	27	14.4
Pennsylvania					
Philadelphia County	498	445	89.4	53	10.6
Tennessee					
Shelby County	259	163	62.9	96	37.1
Texas					
Bexar County	348	239	68.7	109	31.3
Dallas County	815	612	75.1	203	24.9
Harris County	1,100	802	72.9	298	27.1
Tarrant County	303	216	71.3	87	28.7
Travis County	210	148	70.5	62	29.5
Washington					
King County	210	196	93.3	14	6.7

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/ μ L) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis. Linkage to HIV medical care was measured by documentation of ≥ 1 CD4 or VL tests ≤ 1 month after HIV diagnosis. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: New Jersey and Pennsylvania (excluding Philadelphia County). Areas with incomplete lab reporting: Arizona, Nevada, and Puerto Rico.

Table 4d. Linkage to HIV medical care within 1 month after HIV diagnosis during 2018, among persons aged ≥13 years, by selected characteristics—41 states and the District of Columbia

	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
Gender					
Male	26,657	21,392	80.2	5,265	19.8
Female	6,299	5,029	79.8	1,270	20.2
Transgender male-to-female ^a	492	396	80.5	96	19.5
Transgender female-to-male ^a	42	32	76.2	10	23.8
Additional gender identity ^b	10	9	90.0	1	10.0
Age at diagnosis (yr)					
13–24	6,997	5,400	77.2	1,597	22.8
25–34	11,998	9,540	79.5	2,458	20.5
35–44	6,452	5,307	82.3	1,145	17.7
45–54	4,719	3,851	81.6	868	18.4
≥55	3,334	2,760	82.8	574	17.2
Race/ethnicity					
American Indian/Alaska Native	140	109	77.9	31	22.1
Asian	786	662	84.2	124	15.8
Black/African American	14,558	11,226	77.1	3,332	22.9
Hispanic/Latino ^c	8,776	7,230	82.4	1,546	17.6
Native Hawaiian/other Pacific Islander	57	50	87.7	7	12.3
White	8,323	6,876	82.6	1,447	17.4
Multiple races	860	705	82.0	155	18.0
Transmission category ^d					
Male-to-male sexual contact	22,237	17,963	80.8	4,273	19.2
Injection drug use					
Male	1,150	875	76.1	275	23.9
Female	898	679	75.6	219	24.4
Male-to-male sexual contact and injection drug use	1,210	963	79.6	247	20.4
Heterosexual contact ^e					
Male	2,533	1,973	77.9	561	22.1
Female	5,411	4,355	80.5	1,056	19.5
Total ^f	33,500	26,858	80.2	6,642	19.8

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data not provided for jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or for areas with incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Puerto Rico, and Vermont.

^a “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^c Hispanics/Latinos can be of any race.

^d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and may include transgender persons.

^e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^f Includes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 4e. Linkage to HIV medical care within 1 month after HIV diagnosis during 2018, among persons aged ≥ 13 years, by area of residence—41 states and the District of Columbia

Area of residence	Total No.	≥ 1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
Alabama	607	488	80.4	119	19.6
Alaska	23	20	87.0	3	13.0
California	4,712	3,744	79.5	968	20.5
Colorado	399	332	83.2	67	16.8
Delaware	92	74	80.4	18	19.6
District of Columbia	275	231	84.0	44	16.0
Florida	4,573	3,766	82.4	807	17.6
Georgia	2,501	1,965	78.6	536	21.4
Hawaii	70	60	85.7	10	14.3
Illinois	1,361	1,086	79.8	275	20.2
Indiana	512	350	68.4	162	31.6
Iowa	115	107	93.0	8	7.0
Louisiana	972	767	78.9	205	21.1
Maine	30	29	96.7	1	3.3
Maryland	996	814	81.7	182	18.3
Massachusetts	650	562	86.5	88	13.5
Michigan	716	590	82.4	126	17.6
Minnesota	288	234	81.2	54	18.8
Mississippi	477	357	74.8	120	25.2
Missouri	447	316	70.7	131	29.3
Montana	23	21	91.3	2	8.7
Nebraska	79	64	81.0	15	19.0
Nevada	503	441	87.7	62	12.3
New Hampshire	38	37	97.4	1	2.6
New Mexico	122	102	83.6	20	16.4
New York	2,456	2,121	86.4	335	13.6
North Carolina	1,187	932	78.5	255	21.5
North Dakota	36	30	83.3	6	16.7
Ohio	977	785	80.3	192	19.7
Oklahoma	280	196	70.0	84	30.0
Oregon	229	188	82.1	41	17.9
Rhode Island	75	68	90.7	7	9.3
South Carolina	715	617	86.3	98	13.7
South Dakota	29	26	89.7	3	10.3
Tennessee	762	559	73.4	203	26.6
Texas	4,388	3,307	75.4	1,081	24.6
Utah	119	99	83.2	20	16.8
Virginia	858	659	76.8	199	23.2
Washington	504	457	90.7	47	9.3
West Virginia	86	70	81.4	16	18.6
Wisconsin	206	178	86.4	28	13.6
Wyoming	12	9	75.0	3	25.0
Total	33,500	26,858	80.2	6,642	19.8

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/ μ L) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis. Linkage to HIV medical care was measured by documentation of ≥ 1 CD4 or VL tests ≤ 1 month after HIV diagnosis. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Puerto Rico, and Vermont.

Table 4f. Linkage to HIV medical care within 1 month after HIV diagnosis during 2018, among persons aged ≥13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
California					
Alameda County	198	164	82.8	34	17.2
Los Angeles County	1690	1,286	76.1	404	23.9
Orange County	286	223	78.0	63	22.0
Riverside County	257	214	83.3	43	16.7
Sacramento County	156	133	85.3	23	14.7
San Bernardino County	274	197	71.9	77	28.1
San Diego County	378	317	83.9	61	16.1
San Francisco County	237	219	92.4	18	7.6
District of Columbia	275	231	84.0	44	16.0
Florida					
Broward County	626	527	84.2	99	15.8
Duval County	274	204	74.5	70	25.5
Hillsborough County	301	248	82.4	53	17.6
Miami-Dade County	1,177	994	84.5	183	15.5
Orange County	464	356	76.7	108	23.3
Palm Beach County	284	232	81.7	52	18.3
Pinellas County	175	151	86.3	24	13.7
Georgia					
Cobb County	153	118	77.1	35	22.9
DeKalb County	362	282	77.9	80	22.1
Fulton County	605	488	80.7	117	19.3
Gwinnett County	151	115	76.2	36	23.8
Illinois					
Cook County	970	777	80.1	193	19.9
Indiana					
Marion County	205	132	64.4	73	35.6
Louisiana					
East Baton Rouge Parish	178	153	86.0	25	14.0
Orleans Parish	179	139	77.7	40	22.3
Maryland					
Baltimore City	231	181	78.4	50	21.6
Montgomery County	126	108	85.7	18	14.3
Prince George's County	308	248	80.5	60	19.5
Massachusetts					
Suffolk County	147	134	91.2	13	8.8
Michigan					
Wayne County	300	245	81.7	55	18.3
Nevada					
Clark County	450	394	87.6	56	12.4

Table 4f. Linkage to HIV medical care within 1 month after HIV diagnosis during 2018, among persons aged ≥13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*cont*)

Area of residence	Total No.	≥1 CD4 or VL tests		No CD4 or VL test	
		No.	%	No.	%
New York					
Bronx County	447	388	86.8	59	13.2
Kings County	548	481	87.8	67	12.2
New York County	371	323	87.1	48	12.9
Queens County	411	371	90.3	40	9.7
North Carolina					
Mecklenburg County	242	191	78.9	51	21.1
Ohio					
Cuyahoga County	149	127	85.2	22	14.8
Franklin County	194	165	85.1	29	14.9
Hamilton County	184	144	78.3	40	21.7
Pennsylvania					
Philadelphia County	442	383	86.7	59	13.3
Tennessee					
Shelby County	303	224	73.9	79	26.1
Texas					
Bexar County	325	223	68.6	102	31.4
Dallas County	785	584	74.4	201	25.6
Harris County	1,199	886	73.9	313	26.1
Tarrant County	275	209	76.0	66	24.0
Travis County	189	151	79.9	38	20.1
Washington					
King County	292	266	91.1	26	8.9

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: New Jersey and Pennsylvania (excluding Philadelphia County). Areas with incomplete lab reporting: Arizona and Puerto Rico.

Table 5a. HIV viral suppression during 2017 among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2016 and alive at year-end 2017, by selected characteristics—41 states and the District of Columbia

	Persons alive at year-end 2017	VL <200 copies/mL	
	No.	No.	%
Gender			
Male	643,720	410,459	63.8
Female	200,524	122,524	61.1
Transgender male-to-female ^a	8,164	5,163	63.2
Transgender female-to-male ^a	301	188	62.5
Additional gender identity ^b	127	80	63.0
Age at year-end 2016 (yr)			
13–24	31,243	17,830	57.1
25–34	131,682	76,975	58.5
35–44	166,076	100,708	60.6
45–54	264,667	172,238	65.1
≥55	259,168	170,663	65.9
Race/ethnicity			
American Indian/Alaska Native	2,063	1,299	63.0
Asian ^c	12,005	8,248	68.7
Black/African American	354,480	204,509	57.7
Hispanic/Latino ^d	189,388	118,407	62.5
Native Hawaiian/other Pacific Islander	692	454	65.6
White	253,048	177,085	70.0
Multiple races	40,502	28,349	70.0
Transmission category^e			
Male-to-male sexual contact	475,435	314,269	66.1
Injection drug use			
Male	56,641	29,536	52.1
Female	40,676	23,851	58.6
Male-to-male sexual contact and injection drug use	48,167	30,602	63.5
Heterosexual contact ^f			
Male	65,307	37,867	58.0
Female	154,080	95,665	62.1
Other ^g			
Male	6,438	3,414	53.0
Female	6,092	3,209	52.7
Total^h	852,836	538,414	63.1

Abbreviations: VL, viral load (copies/mL); CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on address of residence as of December 31, 2017 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2017. Data not provided for states and associated counties that lack laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Kansas, Kentucky, Nevada, Puerto Rico, and Vermont.

^a “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^c Includes Asian/Pacific Islander legacy cases.

^d Hispanics/Latinos can be of any race.

^e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and may include transgender persons.

^f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^g Includes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified.

^h Includes 658 persons of unknown race/ethnicity.

Table 5b. HIV viral suppression during 2017 among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2016 and alive at year-end 2017, by area of residence—41 states and the District of Columbia

Area of residence	Persons alive at year-end 2017	VL <200 copies/mL	
	No.	No.	%
Alabama	12,403	7,886	63.6
Alaska	685	541	79.0
California	123,480	82,379	66.7
Colorado	11,764	6,960	59.2
Connecticut	10,065	6,729	66.9
Delaware	3,162	2,145	67.8
District of Columbia	13,975	7,821	56.0
Florida	104,246	66,619	63.9
Georgia	50,224	29,466	58.7
Hawaii	2,413	1,668	69.1
Illinois	33,658	18,249	54.2
Indiana	10,597	6,562	61.9
Iowa	2,544	2,025	79.6
Louisiana	19,393	12,567	64.8
Maine	1,522	1,203	79.0
Maryland	31,627	18,276	57.8
Massachusetts	19,819	14,033	70.8
Michigan	14,894	10,758	72.2
Minnesota	7,993	5,547	69.4
Mississippi	8,921	4,418	49.5
Missouri	11,796	7,820	66.3
Montana	582	463	79.6
Nebraska	2,027	1,311	64.7
New Hampshire	1,149	812	70.7
New Mexico	3,253	2,238	68.8
New York	123,484	78,126	63.3
North Carolina	29,610	18,752	63.3
North Dakota	374	290	77.5
Ohio	20,896	11,449	54.8
Oklahoma	5,742	3,421	59.6
Oregon	6,662	5,256	78.9
Rhode Island	2,461	1,891	76.8
South Carolina	16,152	10,722	66.4
South Dakota	532	296	55.6
Tennessee	15,973	9,199	57.6
Texas	83,827	51,385	61.3
Utah	2,631	1,651	62.8
Virginia	21,599	11,748	54.4
Washington	12,739	10,035	78.8
West Virginia	1,723	1,020	59.2
Wisconsin	5,927	4,436	74.8
Wyoming	312	241	77.2
Total	852,836	538,414	63.1

Abbreviations: VL, viral load (copies/mL); CD4, CD4+ T-lymphocyte count (cells/ μ L) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on address of residence as of December 31, 2017 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2017. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Kansas, Kentucky, Nevada, Puerto Rico, and Vermont.

Table 5c. HIV viral suppression during 2017 among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2016 and alive at year-end 2017, by area of residence—Ending the HIV Epidemic Phase I jurisdictions

Area of residence	Persons alive at year-end 2017	VL <200 copies/mL	
	No.	No.	%
California			
Alameda County	5,679	4,175	73.5
Los Angeles County	46,844	29,801	63.6
Orange County	6,486	4,047	62.4
Riverside County	8,243	6,358	77.1
Sacramento County	4,014	2,903	72.3
San Bernardino County	3,857	2,136	55.4
San Diego County	12,552	7,799	62.1
San Francisco County	12,070	9,283	76.9
District of Columbia	13,975	7,821	56.0
Florida			
Broward County	18,513	12,499	67.5
Duval County	5,607	3,156	56.3
Hillsborough County	6,357	4,194	66.0
Miami-Dade County	24,869	14,919	60.0
Orange County	7,885	5,065	64.2
Palm Beach County	7,545	4,459	59.1
Pinellas County	4,285	2,939	68.6
Georgia			
Cobb County	2,853	1,787	62.6
DeKalb County	7,833	4,846	61.9
Fulton County	13,748	8,209	59.7
Gwinnett County	2,578	1,648	63.9
Illinois			
Cook County	23,983	13,093	54.6
Indiana			
Marion County	4,313	2,995	69.4
Louisiana			
East Baton Rouge Parish	3,671	2,458	67.0
Orleans Parish	4,649	3,088	66.4
Maryland			
Baltimore City	9,995	5,413	54.2
Montgomery County	3,193	1,612	50.5
Prince George's County	5,678	3,228	56.9
Massachusetts			
Suffolk County	5,610	3,951	70.4
Michigan			
Wayne County	6,122	4,172	68.1
New York			
Bronx County	26,861	16,690	62.1
Kings County	25,672	16,305	63.5
New York County	26,680	16,502	61.9
Queens County	15,230	9,659	63.4
North Carolina			
Mecklenburg County	5,428	3,524	64.9
Ohio			
Cuyahoga County	4,481	2,112	47.1
Franklin County	4,557	2,854	62.6
Hamilton County	2,712	1,188	43.8

Table 5c. HIV viral suppression during 2017 among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2016 and alive at year-end 2017, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*cont*)

Area of residence	Persons alive at year-end 2017	VL <200 copies/mL	
	No.	No.	%
Pennsylvania			
Philadelphia County	16,616	10,275	61.8
Tennessee			
Shelby County	5,847	3,624	62.0
Texas			
Bexar County	5,774	3,754	65.0
Dallas County	16,611	10,169	61.2
Harris County	23,776	14,231	59.9
Tarrant County	5,206	3,462	66.5
Travis County	4,505	3,416	75.8
Washington			
King County	6,609	5,394	81.6

Abbreviations: VL, viral load (copies/mL); CD4, CD4+ T-lymphocyte count (cells/ μ L) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on address of residence as of December 31, 2017 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2017. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: New Jersey and Pennsylvania (excluding Philadelphia County). Areas with incomplete lab reporting: Arizona, Nevada (2017 only), and Puerto Rico.

Table 5d. HIV viral suppression during 2018 among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2017 and alive at year-end 2018, by selected characteristics—41 states and the District of Columbia

	Persons alive at year-end 2018	VL <200 copies/mL	
	No.	No.	%
Gender			
Male	662,766	431,743	65.1
Female	202,366	127,475	63.0
Transgender male-to-female ^a	8,625	5,643	65.4
Transgender female-to-male ^a	326	233	71.5
Additional gender identity ^b	147	101	68.7
Age at year-end 2017 (yr)			
13–24	29,983	18,084	60.3
25–34	137,595	83,601	60.8
35–44	167,518	104,524	62.4
45–54	256,520	169,741	66.2
≥55	282,614	189,245	67.0
Race/ethnicity			
American Indian/Alaska Native	2,234	1,429	64.0
Asian ^c	13,096	9,121	69.6
Black/African American	363,079	217,479	59.9
Hispanic/Latino ^d	195,295	124,483	63.7
Native Hawaiian/other Pacific Islander	749	490	65.4
White	258,318	182,545	70.7
Multiple races	40,800	29,585	72.5
Transmission category^e			
Male-to-male sexual contact	495,978	333,757	67.3
Injection drug use			
Male	54,647	29,095	53.2
Female	39,746	24,001	60.4
Male-to-male sexual contact and injection drug use	48,506	31,622	65.2
Heterosexual contact ^f			
Male	65,946	39,468	59.8
Female	156,762	100,284	64.0
Other ^g			
Male	6,437	3,526	54.8
Female	6,208	3,440	55.4
Total^h	874,230	565,195	64.7

Abbreviations: VL, viral load (copies/mL); CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data for the year 2018 are preliminary and based on death data reported to CDC as of December 2019. Data are based on address of residence as of December 31, 2018 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2018. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Puerto Rico, and Vermont.

^a “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

^b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

^c Includes Asian/Pacific Islander legacy cases.

^d Hispanics/Latinos can be of any race.

^e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data presented based on sex at birth and may include transgender persons.

^f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.

^g Includes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified.

^h Includes 659 persons of unknown race/ethnicity.

Table 5e. HIV viral suppression during 2018 among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2017 and alive at year-end 2018, by area of residence—41 states and the District of Columbia

Area of residence	Persons alive at year-end 2018	VL <200 copies/mL	
	No.	No.	%
Alabama ^a	12,969	8,550	65.9
Alaska	684	530	77.5
California	126,348	84,492	66.9
Colorado	12,256	7,347	59.9
Delaware	3,226	2,343	72.6
District of Columbia	13,918	7,778	55.9
Florida	106,456	70,002	65.8
Georgia	52,147	31,083	59.6
Hawaii	2,366	1,716	72.5
Illinois	34,458	19,710	57.2
Indiana	10,998	6,842	62.2
Iowa	2,678	2,156	80.5
Louisiana	19,960	13,345	66.9
Maine	1,561	1,228	78.7
Maryland	32,163	20,195	62.8
Massachusetts	20,080	14,196	70.7
Michigan	15,294	11,188	73.2
Minnesota	8,278	5,498	66.4
Mississippi	9,012	4,536	50.3
Missouri	12,176	7,746	63.6
Montana	619	507	81.9
Nebraska	2,095	1,383	66.0
Nevada	9,723	6,115	62.9
New Hampshire	1,219	902	74.0
New Mexico	3,462	2,467	71.3
New York	124,567	80,729	64.8
North Carolina	30,665	20,516	66.9
North Dakota	417	326	78.2
Ohio	21,458	12,625	58.8
Oklahoma ^a	5,970	3,528	59.1
Oregon	6,826	5,397	79.1
Rhode Island	2,519	1,988	78.9
South Carolina ^a	16,706	11,401	68.2
South Dakota	581	338	58.2
Tennessee	16,601	10,580	63.7
Texas	87,350	54,218	62.1
Utah	2,811	1,910	67.9
Virginia	22,240	13,454	60.5
Washington	13,115	10,413	79.4
West Virginia	1,811	1,136	62.7
Wisconsin	6,114	4,525	74.0
Wyoming	333	256	76.9
Total	874,230	565,195	64.7

Abbreviations: VL, viral load (copies/mL); CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data for the year 2018 are preliminary and based on death data reported to CDC as of December 2019. Data are based on address of residence as of December 31, 2018 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2018. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho, New Jersey, and Pennsylvania. Areas with incomplete lab reporting: Arizona, Arkansas, Connecticut, Kansas, Kentucky, Puerto Rico, and Vermont.

^a Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2018.

Table 5f. HIV viral suppression during 2018 among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2017 and alive at year-end 2018, by area of residence—Ending the HIV Epidemic Phase I jurisdictions

Area of residence	Persons alive at year-end 2018	VL <200 copies/mL	
	No.	No.	%
California			
Alameda County	5,856	4,342	74.1
Los Angeles County	47,773	29,992	62.8
Orange County	6,596	3,995	60.6
Riverside County	8,767	6,822	77.8
Sacramento County	4,124	3,004	72.8
San Bernardino County	4,193	2,407	57.4
San Diego County	12,747	8,070	63.3
San Francisco County	11,912	9,154	76.8
District of Columbia	13,918	7,778	55.9
Florida			
Broward County	18,862	12,867	68.2
Duval County	5,819	3,496	60.1
Hillsborough County	6,566	4,539	69.1
Miami-Dade County	25,168	15,543	61.8
Orange County	8,157	5,418	66.4
Palm Beach County	7,641	4,704	61.6
Pinellas County	4,291	3,029	70.6
Georgia			
Cobb County	3,008	1,874	62.3
DeKalb County	8,121	5,107	62.9
Fulton County	14,524	8,795	60.6
Gwinnett County	2,730	1,764	64.6
Illinois			
Cook County	24,232	13,460	55.5
Indiana			
Marion County	4,485	3,060	68.2
Louisiana			
East Baton Rouge Parish	3,749	2,676	71.4
Orleans Parish	4,760	3,210	67.4
Maryland			
Baltimore City	9,254	5,485	59.3
Montgomery County	3,457	1,873	54.2
Prince George's County	5,535	3,358	60.7
Massachusetts			
Suffolk County	5,587	3,983	71.3
Michigan			
Wayne County	6,450	4,461	69.2
Nevada			
Clark County	8,165	5,238	64.2
New York			
Bronx County	27,127	17,903	66.0
Kings County	25,945	16,634	64.1
New York County	26,731	16,840	63.0
Queens County	15,463	9,740	63.0
North Carolina			
Mecklenburg County	5,638	3,807	67.5

Table 5f. HIV viral suppression during 2018 among persons aged ≥ 13 years with HIV infection diagnosed by year-end 2017 and alive at year-end 2018, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (*cont*)

Area of residence	Persons alive at year-end 2018	VL <200 copies/mL	
	No.	No.	%
Ohio			
Cuyahoga County	4,570	2,815	61.6
Franklin County	4,631	3,003	64.8
Hamilton County	2,778	1,290	46.4
Pennsylvania			
Philadelphia County	16,525	10,295	62.3
Tennessee			
Shelby County	5,922	3,805	64.3
Texas			
Bexar County	5,985	3,883	64.9
Dallas County	17,345	10,705	61.7
Harris County	24,489	15,066	61.5
Tarrant County	5,453	3,546	65.0
Travis County	4,724	3,463	73.3
Washington			
King County	6,619	5,453	82.4

Abbreviations: VL, viral load (copies/mL); CD4, CD4+ T-lymphocyte count (cells/ μ L) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data for the year 2018 are preliminary and based on death data reported to CDC as of December 2019. Data are based on address of residence as of December 31, 2018 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2018. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: New Jersey and Pennsylvania (excluding Philadelphia County). Areas with incomplete lab reporting: Arizona and Puerto Rico.

Table 6a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2017, among persons aged ≥ 16 years, by selected characteristics—United States

	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
Sex at birth			
Male	142,409	986,476	14.4
Female	9,910	225,301	4.4
Age at infection (yr)			
16–24	19,120	253,709	7.5
25–34	62,163	423,548	14.7
35–44	36,022	233,252	15.4
45–54	23,549	180,400	13.1
≥55	11,549	120,868	9.6
Race/ethnicity^d			
Asian/Other	6,730	n/a	n/a
Black/African American	19,068	479,443	4.0
Hispanic/Latino	22,124	307,689	7.2
White	104,254	350,238	29.8
Total	152,403	1,211,777	12.6

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available.

^a Estimated using 2017 data from IQVIA pharmacy database.

^b Estimated using 2017 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and American Census Survey.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

^d Race/ethnicity data were only available for 37% of persons prescribed PrEP in 2017. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.

Table 6b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2017, among persons aged ≥ 16 years, by area of residence—United States and Puerto Rico

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
Alabama	949	11,421	8.3
Alaska	116	2,288	5.1
Arizona	2,219	26,829	8.3
Arkansas	421	4,878	8.6
California	26,343	165,645	15.9
Colorado	2,385	25,695	9.3
Connecticut	1,574	10,741	14.7
Delaware	265	4,600	5.8
District of Columbia	3,738	13,752	27.2
Florida	7,811	122,502	6.4
Georgia	4,313	40,504	10.6
Hawaii	427	5,490	7.8
Idaho	253	3,761	6.7
Illinois	10,252	53,854	19.0
Indiana	1,498	21,441	7.0
Iowa	789	4,209	18.7
Kansas	543	5,449	10.0
Kentucky	761	13,342	5.7
Louisiana	2,347	15,231	15.4
Maine	253	3,271	7.7
Maryland	2,690	27,978	9.6
Massachusetts	5,886	24,507	24.0
Michigan	2,195	28,239	7.8
Minnesota	2,499	23,417	10.7
Mississippi	447	5,072	8.8
Missouri	1,902	19,545	9.7
Montana	118	2,629	4.5
Nebraska	359	2,597	13.8
Nevada	1,019	10,904	9.3
New Hampshire	292	2,372	12.3
New Jersey	3,227	27,723	11.6
New Mexico	572	6,598	8.7
New York	22,572	74,419	30.3
North Carolina	2,337	33,179	7.0
North Dakota	108	1,119	9.7
Ohio	3,307	40,578	8.1
Oklahoma	531	10,820	4.9
Oregon	2,035	20,255	10.0
Pennsylvania	6,042	36,617	16.5
Puerto Rico	116	n/a ^d	n/a
Rhode Island	608	4,449	13.7
South Carolina	662	10,249	6.5
South Dakota	56	934	6.0
Tennessee	1,685	22,898	7.4
Texas	11,048	123,538	8.9
Utah	1,019	6,831	14.9
Vermont	198	1,491	13.3
Virginia	2,038	33,424	6.1
Washington	6,707	35,255	19.0
West Virginia	221	3,706	6.0
Wisconsin	1,402	14,121	9.9
Wyoming	47	1,411	3.3

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available.

^a Estimated using 2017 data from IQVIA pharmacy database.

^b Estimated using 2017 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and American Census Survey.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

^d Population-based data not available to make the estimate.

Table 6c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2017, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
Arizona			
Maricopa County	1,804	17,228	10.5
California			
Alameda County	1,359	7,296	18.6
Los Angeles County	9,011	41,822	21.5
Orange County	1,033	10,094	10.2
Riverside County	845	11,163	7.6
Sacramento County	542	5,381	10.1
San Bernardino County	377	12,132	3.1
San Diego County	2,326	15,150	15.4
San Francisco County	6,384	11,427	55.9
District of Columbia	3,738	13,752	27.2
Florida			
Broward County	1,778	17,445	10.2
Duval County	230	8,533	2.7
Hillsborough County	471	12,578	3.7
Miami-Dade County	1,928	22,227	8.7
Orange County	929	15,027	6.2
Palm Beach County	337	7,647	4.4
Pinellas County	420	10,502	4.0
Georgia			
Cobb County	254	3,396	7.5
DeKalb County	844	5,921	14.3
Fulton County	1,853	11,112	16.7
Gwinnett County	299	3,374	8.9
Illinois			
Cook County	8,594	37,802	22.7
Indiana			
Marion County	649	7,555	8.6
Louisiana			
East Baton Rouge Parish	207	1,221	17.0
Orleans Parish	1,035	5,231	19.8
Maryland			
Baltimore City	403	6,304	6.4
Montgomery County	543	5,551	9.8
Prince George's County	435	3,640	12.0
Massachusetts			
Suffolk County	1,969	6,025	32.7
Michigan			
Wayne County	643	8,796	7.3
Nevada			
Clark County	865	8,847	9.8
New Jersey			
Essex County	400	5,134	7.8
Hudson County	616	4,333	14.2

Table 6c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2017, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
New York			
Bronx County	1,309	5,957	22.0
Kings County	4,589	13,551	33.9
New York County	9,609	14,657	65.6
Queens County	2,518	8,846	28.5
North Carolina			
Mecklenburg County	583	8,499	6.9
Ohio			
Cuyahoga County	578	7,416	7.8
Franklin County	1,207	12,302	9.8
Hamilton County	265	6,568	4.0
Pennsylvania			
Philadelphia County	2,301	7,710	29.8
Puerto Rico			
San Juan Municipio	n/a ^d	n/a ^e	n/a
Tennessee			
Shelby County	293	7,213	4.1
Texas			
Bexar County	623	11,609	5.4
Dallas County	2,132	22,093	9.7
Harris County	2,512	30,800	8.2
Tarrant County	672	11,757	5.7
Travis County	2,144	10,725	20.0
Washington			
King County	4,853	11,680	41.5

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available.

^a Estimated using 2017 data from IQVIA pharmacy database.

^b Estimated using 2017 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and American Census Survey.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

^d Because of reliability concerns, PrEP prescription data for the jurisdiction are not reported.

^e Population-based data not available to make the estimate.

Table 6d. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2018, among persons aged ≥ 16 years, by selected characteristics—United States

	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
Sex at birth			
Male	204,812	986,476	20.8
Female	14,770	225,301	6.6
Age at infection (yr)			
16–24	28,860	253,709	11.4
25–34	91,077	423,548	21.5
35–44	51,083	233,252	21.9
45–54	31,300	180,400	17.4
≥55	17,371	120,868	14.4
Race/ethnicity^d			
Asian/Other	9,437	n/a	n/a
Black/African American	28,243	479,443	5.9
Hispanic/Latino	33,503	307,689	10.9
White	147,454	350,238	42.1
Total	219,691	1,211,777	18.1

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available.

^a Estimated using 2018 data from IQVIA pharmacy database.

^b Estimated using 2017 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and American Census Survey.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

^d Race/ethnicity data were only available for 35% of persons prescribed PrEP in 2018. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.

Table 6e. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2018, among persons aged ≥ 16 years, by area of residence—United States

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
Alabama	1,513	11,421	13.2
Alaska	189	2,288	8.3
Arizona	3,521	26,829	13.1
Arkansas	611	4,878	12.5
California	36,272	165,645	21.9
Colorado	3,428	25,695	13.3
Connecticut	2,292	10,741	21.3
Delaware	402	4,600	8.7
District of Columbia	5,014	13,752	36.5
Florida	13,623	122,502	11.1
Georgia	6,154	40,504	15.2
Hawaii	668	5,490	12.2
Idaho	377	3,761	10.0
Illinois	14,438	53,854	26.8
Indiana	2,170	21,441	10.1
Iowa	1,184	4,209	28.1
Kansas	759	5,449	13.9
Kentucky	1,231	13,342	9.2
Louisiana	3,468	15,231	22.8
Maine	390	3,271	11.9
Maryland	4,008	27,978	14.3
Massachusetts	8,195	24,507	33.4
Michigan	3,453	28,239	12.2
Minnesota	3,542	23,417	15.1
Mississippi	654	5,072	12.9
Missouri	2,781	19,545	14.2
Montana	173	2,629	6.6
Nebraska	487	2,597	18.8
Nevada	1,477	10,904	13.5
New Hampshire	497	2,372	21.0
New Jersey	4,652	27,723	16.8
New Mexico	790	6,598	12.0
New York	30,572	74,419	41.1
North Carolina	3,682	33,179	11.1
North Dakota	166	1,119	14.8
Ohio	4,715	40,578	11.6
Oklahoma	827	10,820	7.6
Oregon	2,753	20,255	13.6
Pennsylvania	8,402	36,617	22.9
Puerto Rico	225	n/a ^d	n/a
Rhode Island	842	4,449	18.9
South Carolina	1,198	10,249	11.7
South Dakota	106	934	11.3
Tennessee	2,602	22,898	11.4
Texas	17,628	123,538	14.3
Utah	1,496	6,831	21.9
Vermont	264	1,491	17.7
Virginia	3,177	33,424	9.5
Washington	8,798	35,255	25.0
West Virginia	358	3,706	9.7
Wisconsin	2,017	14,121	14.3
Wyoming	70	1,411	5.0

Abbreviation: PrEP, preexposure prophylaxis.

^a Estimated using 2018 data from IQVIA pharmacy database.

^b Estimated using 2017 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and American Census Survey.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

^d Population-based data not available to make the estimate.

Table 6f. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2018, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
Arizona			
Maricopa County	2,860	17,228	16.6
California			
Alameda County	1,844	7,296	25.3
Los Angeles County	12,121	41,822	29.0
Orange County	1,607	10,094	15.9
Riverside County	1,287	11,163	11.5
Sacramento County	740	5,381	13.8
San Bernardino County	579	12,132	4.8
San Diego County	3,347	15,150	22.1
San Francisco County	8,121	11,427	71.1
District of Columbia	5,014	13,752	36.5
Florida			
Broward County	2,701	17,445	15.5
Duval County	365	8,533	4.3
Hillsborough County	751	12,578	6.0
Miami-Dade County	3,801	22,227	17.1
Orange County	1,711	15,027	11.4
Palm Beach County	555	7,647	7.3
Pinellas County	704	10,502	6.7
Georgia			
Cobb County	375	3,396	11.0
DeKalb County	1,159	5,921	19.6
Fulton County	2,502	11,112	22.5
Gwinnett County	449	3,374	13.3
Illinois			
Cook County	11,897	37,802	31.5
Indiana			
Marion County	836	7,555	11.1
Louisiana			
East Baton Rouge Parish	441	1,221	36.1
Orleans Parish	1,399	5,231	26.7
Maryland			
Baltimore City	548	6,304	8.7
Montgomery County	803	5,551	14.5
Prince George's County	658	3,640	18.1
Massachusetts			
Suffolk County	2,628	6,025	43.6
Michigan			
Wayne County	982	8,796	11.2
Nevada			
Clark County	1,251	8,847	14.1
New Jersey			
Essex County	628	5,134	12.2
Hudson County	867	4,333	20.0

Table 6f. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2018, among persons aged ≥ 16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions (cont)

Area of residence	Persons prescribed PrEP ^a	Persons with PrEP indications ^b	PrEP coverage ^c
	No.	No.	%
New York			
Bronx County	1,998	5,957	33.5
Kings County	6,249	13,551	46.1
New York County	12,661	14,657	86.4
Queens County	3,342	8,846	37.8
North Carolina			
Mecklenburg County	894	8,499	10.5
Ohio			
Cuyahoga County	805	7,416	10.9
Franklin County	1,588	12,302	12.9
Hamilton County	442	6,568	6.7
Pennsylvania			
Philadelphia County	3,143	7,710	40.8
Puerto Rico			
San Juan Municipio	n/a ^d	n/a ^e	n/a
Tennessee			
Shelby County	469	7,213	6.5
Texas			
Bexar County	1,054	11,609	9.1
Dallas County	3,172	22,093	14.4
Harris County	3,987	30,800	12.9
Tarrant County	1,187	11,757	10.1
Travis County	3,438	10,725	32.1
Washington			
King County	6,140	11,680	52.6

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available.

^a Estimated using 2018 data from IQVIA pharmacy database.

^b Estimated using 2017 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and American Census Survey.

^c PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

^d Because of reliability concerns, PrEP prescription data for the jurisdiction are not reported.

^e Population-based data not available to make the estimate.

Table 7. Ending the HIV Epidemic Phase I jurisdictions

Counties	Territories	States
Arizona^a	Puerto Rico^{a,b}	Alabama
Maricopa County ^a	San Juan Municipio ^{a,b}	Arkansas
California		Kentucky
Alameda County		Mississippi
Los Angeles County		Missouri
Orange County		Oklahoma
Riverside County		South Carolina
Sacramento County		
San Bernardino County		
San Diego County		
San Francisco County		
District of Columbia		
Florida		
Broward County		
Duval County		
Hillsborough County		
Miami-Dade County		
Orange County		
Palm Beach County		
Pinellas County		
Georgia		
Cobb County		
DeKalb County		
Fulton County		
Gwinnett County		
Illinois		
Cook County		
Indiana		
Marion County		
Louisiana		
East Baton Rouge Parish		
Orleans Parish		
Maryland		
Baltimore City		
Montgomery County		
Prince George's County		
Massachusetts		
Suffolk County		
Michigan		
Wayne County		
Nevada^a		
Clark County ^a		
New Jersey^c		
Essex County ^c		
Hudson County ^c		
New York		
Bronx County		
Kings County		
New York County		
Queens County		

Table 7. Ending the HIV Epidemic Phase I jurisdictions (cont)

Counties	Territories	States
North Carolina		
Mecklenburg County		
Ohio		
Cuyahoga County		
Franklin County		
Hamilton County		
Pennsylvania^c		
Philadelphia County		
Tennessee		
Shelby County		
Texas		
Bexar County		
Dallas County		
Harris County		
Tarrant County		
Travis County		
Washington		
King County		

Abbreviations: CDC, the Centers for Disease Control and Prevention [footnotes only]; PrEP, preexposure prophylaxis [footnotes only]; CD4, CD4+ T-lymphocyte count (cells/ μ L) or percentage [footnotes only].

Note. For more information on the Ending the HIV Epidemic: A Plan for America initiative, see <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>. Estimates of HIV incidence and knowledge of status not provided for Phase I counties and territories (except the District of Columbia).

^a Linkage to care and viral suppression data are not provided for states and associated counties that have incomplete reporting of laboratory data to CDC: Arkansas, Arizona, Kansas, Kentucky, Nevada, Puerto Rico, and Vermont.

^b Because of reliability concerns, PrEP data are not reported.

^c Linkage to care and viral suppression data are not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral load laboratory results: Idaho, New Jersey, and Pennsylvania (excluding Philadelphia County).